and related terms
Video: Search by Themes (YouTube)
(2 min 40 sec) Recorded April 2014 Transcript
Most research articles will identify where more research is needed. To identify research trends, use the literature review matrix to track where further research is needed.
There is no consistent section in research articles where the authors identify where more research is needed. Pay attention to these sections:
Departments.
Walden University is a member of Adtalem Global Education, Inc. www.adtalem.com Walden University is certified to operate by SCHEV © 2024 Walden University LLC. All rights reserved.
UNE Library Services
Gaps in the literature.
Gaps in the literature are missing pieces or insufficient information in the published research on a topic. These are areas that have opportunities for further research because they are unexplored, under-explored, or outdated.
Gaps can be missing or incomplete:
Conduct a thorough literature search to find a broad range of research articles on your topic. Search research databases ; you can find recommended databases for your subject area in research by subject for your course or program.
If you do not find articles in your literature search, this may indicate a gap.
If you do find articles, the goal is to find a gap for contributing new research. Authors signal that there is a gap using phrases such as:
If you have questions on this, or another, topic, contact a librarian for help!
Select Page
Posted by Md. Harun Ar Rashid | Nov 30, 2022 | Research Methodology
A research gap ( which indicates a lack of prior research on a topic ) is essentially an unanswered question or unsolved issue in a certain discipline. Alternatively, when there is a good number of studies conducted but the findings reflect in multiple ways, making it difficult to draw solid conclusions, there may be a research gap. Let’s take an example; where the goal of your study is to determine the cause (or causes) of a specific disease. In the literature, there is evidence to suggest that smoking is a major contributing factor, but there is also a substantial body of data that shows no connection between smoking and the disease. In that scenario, you may find a research gap that needs further investigation. In the rest of this article, we are going to know about the different types of research gaps in literature review and how to find a research gap .
A research gap is essentially an unanswered question or unresolved problem in a field, reflecting a lack of existing research ( Grad Coach ).
A research gap is a key problem or a question that has not been answered by any of the existing studies within your area of research ( Dr. Sowndarya Somasundaram ).
From the above definitions, we can say that a research gap is a topic or area where there is a lack of information or insufficient data that prevents reviewers to grasp a conclusion regarding a particular question.
According to (Robinson, et al., (2011), Muller-Bloch, & Kranz (2015), and Miles (2017); the research gap can be classified into seven categories which are briefly being:
1. Evidence Gap: An evidence gap occurs with a provocative exception arising if a new research finding contradicts widely accepted conclusions. This gap involves contradictions in the findings of the prior research. It occurs if results from studies allow for conclusions in their own right, but are contradictory when examined from a more abstract point of view. The identification of contradictory evidence starts with analyzing each research stream. Subsequently, the results from these analyses need to be synthesized in order to reveal contradictory evidence.
2. Knowledge Gap: The knowledge gap is a common gap in prior research. There are two settings where a knowledge gap (knowledge void) might occur. First, knowledge may not exist in the actual field of theories and literature from related research domains. Second, it might be the case that the results of a study differ from what was expected.
3. Practical-Knowledge Conflict Gap: This kind of gap tends to be a discrepancy that can motivate new research in this direction. A practical–knowledge (action-knowledge) conflict arises when the actual behavior of professionals is different from their advocated behavior. In this case, the research could seek to determine the scope of the conflict and uncover the reasons for its existence.
4. Methodological Gap: A methodological gap is the type of gap that deals with the conflict that occurs due to the influence of methodology on research results. This gap addresses the conflicts with the research methods in the prior studies and offers a new line of research that is divergent from those research methods. It is noted that it might be useful to various research methods, especially if certain research topics have been mainly explored using a singular or common method.
5. Empirical Gap: An empirical gap is the type of gap that deals with gaps in prior research. This conflict deals with the research findings or propositions that need to be evaluated or empirically verified. For example, the empirical gap often addresses conflicts that no study to date has directly attempted to evaluate a subject or topic from an empirical approach.
6. Theoretical Gap: The theoretical gap is the type of gap that deals with the gaps in theory with prior research. For example, if one phenomenon is being explained through various theoretical models, similar to a methodological gap conflict, there might be a theoretical conflict. Researchers and scholars could examine whether one of those theories is superior in terms of the gap in the prior research. Theoretical gaps are a common occurrence in examining prior research on a phenomenon.
7. Population Gap: A population gap is a common gap recognized among researchers. There are always under-served populations that have been under-researched. This gap is the type of research regarding the population that is not adequately represented or under-researched in the evidence base or prior research (e.g., gender, race/ethnicity, age, etc).
Start with a broad topic related to your field of interest: A broad topic allows you more opportunities to find a research gap. Pick a topic that interests you and that you already know something about. As you learn more about your topic, you can narrow it down further to help you find your focus.
Conduct preliminary research to explore your topic: Begin with a simple online search to learn the basics of a topic. Read encyclopedia entries, journal articles, and recent news articles related to your topic. Then, search online databases for peer-reviewed journal articles related to your topic of study.
Compile a wide range of articles about your topic: Search for different types of articles, like informative texts, research texts, and meta-analyses. This will provide you with a broader understanding of your topic so you can more easily find a gap.
Once you’ve gathered a meaty collection of resources, the section that you really want to focus on is the one titled “further research opportunities” or “further research is needed”. In this section, the researchers will explicitly state where more studies are required – in other words, where potential research gaps may exist. You can also look at the “limitations” section of the studies, as this will often spur ideas for methodology-based research gaps.
By following this process, you’ll orient yourself with the current state of research, which will lay the foundation for you to identify potential research gaps. You can then start drawing up a shortlist of ideas and evaluating them as candidate topics. But remember, make sure you’re looking at recent articles – there’s no use going down a rabbit hole only to find that someone’s already filled the gap.
References:
Former Student at Rajshahi University
Related posts.
August 2, 2019
February 1, 2024
July 6, 2020
January 10, 2024
Library & Information Management Community
M | T | W | T | F | S | S |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 |
8 | 9 | 10 | 11 | 12 | 13 | 14 |
15 | 16 | 17 | 18 | 19 | 20 | 21 |
22 | 23 | 24 | 25 | 26 | 27 | 28 |
29 | 30 | 31 |
Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser .
Enter the email address you signed up with and we'll email you a reset link.
2020, Research to Action: The Global Guide to Research Impact
The basics of research are seemingly clear. Read a lot of articles, see what’s missing, and conduct research to fill the gap in the literature. Wait a minute. What is that? “See what’s missing?” How can we see something that is not there? In this post, we will show you how to “see the invisible;” How to identify the missing pieces in any study, literature review, or program analysis. With these straight-forward techniques, you will be able to better target your research in a more cost-effective way to fill those knowledge gaps to develop more effective theories, plans, and evaluations.
ISSAH BAAKO
Various researchers have established the need for researchers to position their research problem in the research gap of the study area. This does not only indicate the relevance of the study but it demonstrates the significant contribution it would make in the field of study. The purpose of this paper is to conduct a systematic literature review on the concept of research gaps and provoke a discussion on the contemporary literature on types of research gaps. The paper discusses the various approaches for researchers to identify, align and position research problems, research design, and methodology in the research gaps to achieve relevance in their findings and study. A systematic review of the current literature on research gaps might assist beginning researchers in the justification of research problems. Given the acceptable tenet of developing a research agenda, design, and development on a research gap, many early career researchers especially (post)graduate students have difficulties in systematically identifying research gaps as a basis for conducting research work. The significance of this paper is twofold. First, it provides a systematic review of literature on the identification of research gaps to undertake research that would challenge assumptions and underlying existing theories in a significant way. Second, it provides a theoretical discussion on the importance of developing research problems on research gaps to structure their study.
Journal of Research Methods and Strategies
D. Anthony Miles
One of the most prevailing issues in the craft of research is to develop a research agenda and build the research on the development of the research gap. Most research of any endeavor is attributed to the development of the research gap, which is a primary basis in the investigation of any problem, phenomenon or scientific question. Given this accepted tenet of engagement in research, surprising in the research fraternity, we do not train researchers on how to systematically identify research gaps as basis for the investigation. This is has continued to be a common problem with novice researchers. Unfailingly, very little theory and research has been developed on identifying research gaps as a basis for a line in inquiry. The purpose of this research is threefold. First, the proposed theoretical framework builds on the five-point theoretical model of Robinson, Saldanhea, and McKoy (2011) on research gaps. Second, this study builds on the six-point theoretical model of Müller-Bloch and Franz (2014) on research gaps. Lastly, the purpose of this research is to develop and propose a theoretical model that is an amalgamation of the two preceding models and re-conceptualizes the research gap concepts and their characteristics. Thus, this researcher proposes a seven-point theoretical model. This article discusses the characteristics of each research and the situation in which its application is warranted in the literature review The significance of this article is twofold. First, this research provides theoretical significance by developing a theoretical model on research gaps. Second, this research attempts to build a solid taxonomy on the different characteristics of research gaps and establish a foundation. The implication for researchers is that research gaps should be structured and characterized based on their functionality. Thus, this provides researchers with a basic framework for identifying them in the literature investigation.
Kayode Oyediran
Problem in a research as well as human body calls for perfect diagnosis of illness. This is important to avoid treating the symptoms instead of the actual disease. A research problem could be identified through professional or/and academic efforts. This poses a lot of problems to students, both at the undergraduate and postgraduate levels, as this determines the title of their articles or research works. Many of them have to submit many topics to their supervisors before one could be reframed and approved. At times, students appealed to their supervisors to provide them with researchable topics. This to the supervisor(s) almost writing the dissertations/theses for them. The argument of this paper is to let students understand "problem identification" using an analogy from the Holy Bible. The study employed a conversation analysis methodology, which is empirically grounded, exploratory in process and inferential. This involves using every conversation between two or more parties to explore facts/lesson. It was recommended that seasoned lecturers should explain to students how to identify research problems using what are familiar to them to make them understand this important aspect of research.
Omini Akpang
Publications
Cherley C Du Plessis
The ability to conduct an explicit and robust literature review by students, scholars or scientists is critical in producing excellent journal articles, academic theses, academic dissertations or working papers. A literature review is an evaluation of existing research works on a specific academic topic, theme or subject to identify gaps and propose future research agenda. Many postgraduate students in higher education institutions lack the necessary skills and understanding to conduct in-depth literature reviews. This may lead to the presentation of incorrect, false or biased inferences in their theses or dissertations. This study offers scientific knowledge on how literature reviews in different fields of study could be conducted to mitigate against biased inferences such as unscientific analogies and baseless recommendations. The literature review is presented as a process that involves several activities including searching, identifying, reading, summarising, compiling, analysing, interpreting and referencing. We hope this article serves as reference material to improve the academic rigour in the literature review chapters of postgraduate students' theses or dissertations. This article prompts established scholars to explore more innovative ways through which scientific literature reviews can be conducted to identify gaps (empirical, knowledge, theoretical, methodological, application and population gap) and propose a future research agenda.
Management Information Systems Quarterly
Richard Watson
Journal of General Internal Medicine
Susanne Hempel
BACKGROUND: Well-defined, systematic, and transparent processes to identify health research gaps, needs, and priorities are vital to ensuring that available funds target areas with the greatest potential for impact. OBJECTIVE: The purpose of this review is to characterize methods conducted or supported by research funding organizations to identify health research gaps, needs, or priorities. METHOD: We searched MEDLINE, PsycINFO, and the Web of Science up to September 2019. Eligible studies reported on methods to identify health research gaps, needs, and priorities that had been conducted or supported by research funding organizations. Using a published protocol, we extracted data on the method, criteria, involvement of stakeholders, evaluations, and whether the method had been replicated (i.e., used in other studies). RESULTS: Among 10,832 citations, 167 studies were eligible for full data extraction. More than half of the studies employed methods to identify both needs and priorities, whereas about a quarter of studies focused singularly on identifying gaps (7%), needs (6%), or priorities (14%) only. The most frequently used methods were the convening of workshops or meetings (37%), quantitative methods (32%), and the James Lind Alliance approach, a multistakeholder research needs and priority setting process (28%). The most widely applied criteria were importance to stakeholders (72%), potential value (29%), and feasibility (18%). Stakeholder involvement was most prominent among clinicians (69%), researchers (66%), and patients and the public (59%). Stakeholders were identified through stakeholder organizations (51%) and purposive (26%) and convenience sampling (11%). Only 4% of studies evaluated the effectiveness of the methods and 37% employed methods that were reproducible and used in other studies. DISCUSSION: To ensure optimal targeting of funds to meet the greatest areas of need and maximize outcomes, a much more robust evidence base is needed to ascertain the effectiveness of methods used to identify research gaps, needs, and priorities.
UNICAF University - Zambia
Ivan Steenkamp
This section contains the four Thematic Gap Analyses and the Cross-Cutting Gap Analysis. Each of the chapters has a lead author (s) as noted on the front page of the chapter. This follows the way that the team has divided-up the responsibilities for each Thematic Area, with a disciplinary specialist (s) taking the lead on each area. The chapters have, however, been reviewed and commented by others in the project team so the analysis and suggested actions and conclusions have the general support of the full project team.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.
Aare 2004 Doing the Public Good Positioning Educational Research International Education Research Conference Proceedings
Pat Thomson
Charles Turkelson
Rebekka Tunombili
International Journal of P R O F E S S I O N A L Business Review
Journal of Practical Studies in Education
Jenine Beekhuyzen
Notchie Angeles
Sid Ahmed KHETTAB
Global Journal of Artificial Intelligence
Oluwatobi Balogun
The Qualitative Report
Janeen T Lamb
Auxiliadora Padilha
Amanda Bolderston
Quality & Quantity, 47, 3249-3259
Raewyn Bassett
European, Mediterranean, and Middle Eastern Conference on Information Systems
Smaa Elnagar
David Nicholas
Tatam Chiway , Abdullah Ramdhani , Muhammad Ali Ramdhani
International Journal on Studies in English Language and Literature
JOSEPHINE DANIELS
David W Armstrong
Frances Slack
Journal of Asian Development
SANIAGO DAKHI
BMC Pulmonary Medicine volume 24 , Article number: 317 ( 2024 ) Cite this article
109 Accesses
Metrics details
Medication non-adherence is a significant problem in patients with Chronic Obstructive Pulmonary Disease (COPD). Efforts to address this issue are receiving increased attention. Simplifying treatment by prescribing single-inhaler triple therapy (SITT) as an alternative to multi-inhaler triple therapy (MITT) or with smart inhalers are often considered potential solutions. However, the actual impact of these innovations on adherence and clinical outcomes is unclear.
To address this knowledge gap we first conducted a literature review focusing on two research questions: 1) the difference in adherence between SITT and MITT users in COPD, and 2) the effect of smart inhalers on adherence in COPD. Separate searches were conducted in PubMed and two authors independently assessed the articles. In addition, we present a protocol for a study to acquire knowledge for the gaps identified.
To address the first research question, 8 trials were selected for further review. All trials were observational, i.e. randomized controlled trials were lacking. Seven of these trials showed higher adherence and/or persistence in patients on SITT compared with patients on MITT. In addition, four studies showed a positive effect of SITT on various clinical outcomes. For the second research question, 11 trials were selected for review. While most of the studies showed a positive effect of smart inhalers on adherence, there was considerable variation in the results regarding their effect on other clinical outcomes.
The TRICOLON (TRIple therapy COnvenience by the use of one or multipLe Inhalers and digital support in ChrONic Obstructive Pulmonary Disease) trial aims to improve understanding regarding the effectiveness of SITT and smart inhalers in enhancing adherence. This open-label, randomized, multi-center study will enroll COPD patients requiring triple therapy at ten participating hospitals. In total, 300 patients will be randomized into three groups: 1) MITT; 2) SITT; 3) SITT with digital support through a smart inhaler and an e-health platform. The follow-up period will be one year, during which three methods of measuring adherence will be used: smart inhaler data, self-reported data using the Test of Adherence to Inhalers (TAI) questionnaire, and drug analysis in scalp hair samples. Finally, differences in clinical outcomes between the study groups will be compared.
Our review suggests promising results concerning the effect of SITT, as opposed to MITT, and smart inhalers on adherence. However, the quality of evidence is limited due to the absence of randomized controlled trials and/or the short duration of follow-up in many studies. Moreover, its impact on clinical outcomes shows considerable variation. The TRICOLON trial aims to provide solid data on these frequently mentioned solutions to non-adherence in COPD. Collecting data in a well-designed randomized controlled trial is challenging, but the design of this trial addresses both the usefulness of SITT and smart inhalers while ensuring minimal interference in participants' daily lives.
NCT05495698 (Clinicaltrials.gov), registered at 08–08-2022. Protocol version: version 5, date 27–02-2023.
Peer Review reports
Chronic obstructive pulmonary disease (COPD) is characterized by chronic respiratory symptoms due to abnormalities in the airways and/or alveoli, resulting in persistent and often progressive airflow obstruction. Inhalation medication is the primary medical treatment, with three types of inhalation medication available as maintenance therapy: 1) long-acting β2-agonist (LABA), 2) long-acting muscarinic antagonist (LAMA), and 3) inhaled corticosteroids (ICS). Triple therapy is defined as treatment with LABA, LAMA and ICS [ 1 ]. Large randomized controlled trials have shown that triple therapy provides clinical benefits compared to dual therapy in patients with moderate-to-severe COPD and a history of exacerbations, particularly when eosinophilia is present [ 2 , 3 , 4 , 5 , 6 ]. Furthermore, two trials suggest that triple therapy reduces mortality in this specific population [ 7 , 8 ]. Triple therapy can be administered through multiple devices, known as multi-inhaler-triple therapy (MITT), or combined in one inhaler, known as single-inhaler-triple therapy (SITT). Assessment of adherence to inhalation therapy is a crucial element in managing COPD patients according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [ 1 ]. Previous studies have shown that medication adherence is poor in patients with COPD. A systematic review showed that non-adherence rates ranged from 22 to 93%, depending on the study population and method of measurement [ 9 ]. Non-adherence is associated with poor clinical and economic outcomes [ 10 , 11 ]. Simplifying treatment with smart-inhalers and prescribing single-inhaler triple therapy (SITT) as an alternative to multi-inhaler triple therapy (MITT) can be considered as potential solutions. Nowadays, the GOLD report (version 2024) acknowledges that a single inhaler may be more convenient compared to multi-inhaler therapy. [ 1 ]. The actual impact of these innovations on adherence is unclear. Therefore, we conducted a literature review to examine the current evidence on these two potential solutions. Should the evidence prove to be insufficient, we wanted to present a protocol for a study to fill this gap.
Adherence is defined as the process by which patients take their medication as prescribed, while persistence refers to the duration from initiation to discontinuation of the treatment. Adherence and persistence are complex constructs, as previously described by Vrijens et al. [ 12 , 13 ]. Various methods can be used to assess medication adherence. Healthcare professionals commonly inquire directly about their patients' adherence. While this approach is straightforward, research has demonstrated its unreliability in comparison to more objective measurement methods. Unstructured self-reports often lead to an overestimation of adherence [ 14 ]. Patients can structurally self-report their adherence using questionnaires, such as the Test of Adherence to Inhalers (TAI). The TAI is developed specifically to measure adherence to inhalation medication in patients with COPD or asthma [ 15 ]. Furthermore, pharmacy data are often used to determine patient’s access to medication over time by calculating the Proportion of Days Covered (PDC). This method may be less reliable due to missing or inaccessible data (e.g. when multiple pharmacies are used) and the uncertainty about whether the patient actually used the medication [ 16 , 17 ]. Smart inhalers offer a more objective method for measuring adherence. These electronic sensors (e-devices) are attached to or integrated into inhalers. Devices range from simple dose counters to advanced devices that provide reminders, feedback, and/or analyse inhalation technique [ 18 ]. Smart inhalers are often integrated with other e-health interventions, such as telemonitoring, personalised feedback with apps, counselling, and training [ 19 , 20 , 21 ]. Finally, hair analysis can provide a bioanalytical assessment of average long-term drug exposure in the human body. This method could potentially provide an objective measure of adherence over the last few months. However, external factors can impact measurement, and only small part of medication that has been present in the systemic blood circulation is built into hair [ 22 ].
First, we present a review of the literature on two strategies to improve adherence. Second, we describe the study protocol of the TRICOLON trial (TRIple therapy COnvenience by the use of one or multipLe Inhalers and digital support in ChrONic Obstructive Pulmonary Disease).
Separate searches were conducted in PubMed based on two research questions: 1) What is the difference in adherence between SITT and MITT users in COPD?, and 2) What is the effect of smart inhalers on adherence in COPD? The selection of articles from the second PubMed search was supplemented by four papers known to the authors or found by snowballing. Two authors independently assessed these articles to determine whether they should be included in this review (LC and JiV). In cases of disagreement, the opinion of a third author was sought (HK). Only original English-language studies were included. Details of the PubMed search and selection process can be found in the Appendix, Suppl.1.
The primary outcome was the adherence and/or persistence to triple therapy. Secondary outcomes were clinical outcomes, such as exacerbations, COPD Assessment Test (CAT) score, and FEV 1 . Each study underwent an evaluation across multiple criteria to assess the evidence supporting the research question. The strength of the study design was rated with stars: one star for retrospective studies, two stars for prospective observational studies or intervention studies without randomization (e.g. before-and-after designs), and three stars for randomised controlled trials. A green smiley indicates statistically significant superior results in the intervention group (either SITT or smart-inhaler group, depending on the research question) compared to the control group; a yellow neutral smiley signifies no difference between the groups, while a red sad smiley denotes statistically significant inferior results in the intervention group compared to the control group. Additionally, a thumbs-up signifies that other clinical outcomes were measured in that study, whereas a thumbs-down indicates the absence of measurements for other clinical outcomes, Tables 1 and 2 .
Adherence to single versus multi inhaler triple therapy.
The first search yielded eighteen articles, Suppl. Figure 1. After the selection process, eight articles were included for further evaluation, Table 1 . None had a randomized controlled design. Four studies compared SITT with MITT in a prospective setting [ 23 , 27 , 28 , 30 ] and four in a retrospective analysis [ 24 , 25 , 26 , 29 ]. The retrospective studies used either anonymized data from electronic health records of patients in primary or secondary care [ 24 , 26 ], or databases of health insurance claims [ 25 , 29 ]. Seven of these studies showed that adherence and/or persistence to SITT was significantly higher compared to MITT in COPD patients [ 23 , 24 , 25 , 27 , 28 , 29 , 30 ]. Deslee et al. presented contrasting findings, showing that while persistence was higher in the SITT group (median 181 versus 135 days), adherence levels were similar in SITT and MITT (85.7% versus 86.1%) [ 26 ]. The seven trials that showed a positive effect of SITT on adherence were heterogeneous in terms of study design, and methods of measurement, type of inhaler, and molecules. Although most studies directly compared SITT with MITT, two of the prospective studies assessed adherence to SITT after switching from either dual therapy or MITT [ 27 , 28 ]. Brusselle et al. reported separate results for former MITT users: 71.9% at baseline, 74.7% three months after switching to SITT, and 83.8% at six months [ 28 ]. In contrast, Gessner et al. did not report separate results for the different treatments at baseline. Therefore, this difference between SITT and the control group should be interpreted with caution [ 27 ].
Five trials investigated the effect of SITT compared to MITT on clinical outcomes. Four of these trials showed a beneficial effect of SITT on clinical outcomes, Table 1 . SITT users had a lower risk of exacerbations compared to MITT users in two studies [ 23 , 28 ]; three studies showed lower CAT-scores and higher FEV 1 in SITT users [ 27 , 28 , 30 ]; and one study showed a reduced all-cause mortality risk in SITT users [HR: 0.475 (0.237–0.952), p = 0.036] [ 23 ]. In contrast to these studies with positive effects of SITT, Bogart et al. showed different results in two different groups of patients. In patients enrolled in Medicare Advantage with Part D (MAPD) insurance, a significant reduction in exacerbations and healthcare utilisation was seen in the SITT group. However, these differences were not statistically significant in the commercially insured patients [ 29 ].
The second part of our literature review investigated the effect of smart inhalers on adherence in patients with COPD and resulted in 78 articles, from which 11 studies were selected, Table 2 . These studies were heterogenetic in terms of number of patients, study design, and type of intervention and/or smart inhaler. Additionally, length of follow-up ranged from 1 to 12 months, with the vast majority (90.9%) having a follow-up period of ≤ 6 months. Seven studies prospectively compared COPD patients who used a smart-inhalers with a control group; four of those had a randomized controlled open-label design. Six of these seven studies showed a statistically better adherence in the intervention group [ 19 , 31 , 32 , 37 , 38 , 40 ]; one prospective study showed no difference in adherence between smart inhaler users and controls [ 33 ]. Four other observational studies showed variable average adherence rates in smart-inhaler users from 44–77%; however, it should be noted that these trials did not include a control group without smart-inhaler [ 34 , 35 , 36 , 39 ].
Nine studies also investigated the effect of smart inhalers on clinical outcomes [ 19 , 31 , 32 , 33 , 35 , 36 , 37 , 38 , 39 ]. These studies showed mixed results, Table 2 . A significant better inhalation technique was seen in two studies [ 31 , 33 ]. The impact of smart inhalers on other clinical outcomes, including exacerbations, disease burden, quality of life assessments, rescue medication usage, hospitalizations, and healthcare utilization, varied across different studies [ 19 , 32 , 33 , 35 , 36 , 37 , 38 , 39 ].
This review suggests promising results concerning the effect of SITT, as opposed to MITT, and smart inhalers on adherence. However, the quality of evidence is limited due to the absence of randomized controlled trials and/or the short duration of follow-up in many studies. Moreover, there is considerable variation in the findings of these studies regarding diverse clinical outcomes. Consequently, there is a clear need for comprehensive randomised controlled trials to evaluate the benefits of SITT versus MITT in COPD, as well as the individual and combined effects of smart inhalers, both on adherence and clinical outcomes.
The TRICOLON study was initiated to provide evidence on two previously mentioned potential solutions for the non-adherence issue in COPD patients. The primary objective is to investigate whether the adherence to SITT is superior to the adherence to MITT over 12 months of treatment and to investigate whether the adherence of SITT users with a smart inhaler and digital support is superior to the adherence of MITT and SITT users without the smart inhaler and digital support. As a secondary objective, three methods of measuring adherence will be compared: smart inhaler data, self-reported data using the Test of Adherence to Inhalers (TAI) questionnaire [ 15 ], and drug analysis of formoterol in scalp hair samples [ 41 ]. Finally, differences in clinical outcomes between the study groups will be examined.
The TRICOLON study is an investigator-initiated, prospective, open-label, randomised, real-world, multicentre study. The study will be conducted at ten hospitals in the Netherlands, Supplement 2. Patients will be recruited from the pulmonary wards or outpatient clinics of the participating hospitals. Informed consent will be obtained by a member of the research team. Participants are randomly assigned in a 1:1:1 ratio to one of three groups: 1) multi-inhaler triple therapy (Bevespi® and Qvar®), 2) single-inhaler triple therapy (Trimbow®), 3) single-inhaler triple therapy (Trimbow®) with digital support, Fig. 1 . The follow-up period will be one year, during which we aim to minimise disruption to their usual care, thus creating a (close to) real-world situation. The study outline is presented in Fig. 2 . Ethical approval for this study was granted by the United Medical Research Ethics Committees (NL79938.100.22). The trial is registered on clinicaltrials.gov (NCT05495698).
Study design. Patients are randomly assigned in a 1:1:1 ratio to one of three groups: 1) multi-inhaler triple therapy (Bevespi® and Qvar®), 2) single-inhaler triple therapy (Trimbow®), 3) single-inhaler triple therapy (Trimbow®) with e-health. The follow-up period is one year
Study program
*time in months
A total of 300 patients will be enrolled. Patients with a diagnosis of COPD and an indication for triple therapy according to their physician following the GOLD report are eligible to participate. Patients are excluded if asthma is the dominant diagnosis (asthma in the past or as a comorbidity is allowed), if patients use nebulizers or if they already use an e-health application for their COPD. The inclusion and exclusion criteria are displayed in Table 3 .
The study groups have uniform doses, identical molecules and doses (beclomethasone 100µg, formoterol 6µg, and glycopyrronium 10µg), and the same device type (pressurised metered dose inhaler). Therefore, the only differentiating factors are the number of devices used and the use of digital support. Digital support comprises the Findair® smart-inhaler, an electronic device that is attached to the inhaler and measures the frequency and time of the actuations, and the Curavista® platform (Gezondheidsmeter PGO), a digital platform that promotes patient self-management by displaying their medication use and providing medication intake reminders [ 31 , 32 ]. Each patient is provided with smart inhalers that are attached to all their inhalers, including the potential rescue medication. This enables the measurement of actuation frequency and timing. The smart-inhalers are linked to the digital platform for data collection. However, it is important to note that only group 3 has access to an overview of the actuations with feedback in the app and reminders, along with full access to the digital platform. Groups 1 and 2 will not receive any reminders and cannot access the digital platform. Their e-health applications are solely used for data collection purposes, ensuring "silent monitoring" that should not influence their adherence.
We aim for all participants to complete the study using the original study medication. However, given the real-world nature of the study, it is possible that patients require a change in medication due to clinical reasons such as side effects or lack of effectiveness. To prevent the loss of these patients from the study, changes in medication are permitted only when absolutely necessary. Data collection will persist via the electronic devices and with the same settings of the app (silent monitoring or full access). Patients who no longer use a pressurized metered dose inhaler will be excluded, as the electronic devices are specifically tailored for this type of inhaler.
The primary outcome is the average adherence to ICS therapy (measured as the number of actuations registered by the smart-inhaler divided by the total number of doses prescribed, in %) over 12 months of treatment. As a secondary outcome, the average adherence to LABA/LAMA in study group 1 will be compared with adherence to ICS in group 1, and with adherence to LABA/LAMA/ICS in groups 2 and 3. Additional secondary outcomes include the percentage of patients with good adherence, defined as an average ICS adherence of more than 80% and less than 110% actuations measured by the smart inhaler; the Test of Adherence to Inhalers (TAI) scores; and drug levels of formoterol in scalp hair. The hair samples will be collected, stored, and prepared according to the guidelines of the Society of Hair Testing [ 42 ]. Additionally, the study will measure changes in Patient Reported Outcome Measures (PROMs), use of rescue medication, number of exacerbations and hospitalizations, healthcare consumption, and spirometry (FEV 1 ). The PROMs are displayed in Supplement 3.
The statistical software G*Power version 3.1.9.6 was used to calculate the sample size. The study aims to compare three groups: group 1 vs group 2, group 2 vs group 3, and group 1 vs group 3. The sample size calculation is based on the comparison of the average adherence in group 1 vs group 2 (so MITT vs SITT without e-health). Based on a previous study [ 19 ], we expect a 15% difference between the groups, with a standard deviation of 30%. The significance level of the test was set at (alpha) 0.0167 using the Holm-Bonferroni method to adjust for multiple testing, as we are comparing three groups (alpha 0.05/3 = 0.0167), with a power of 80%. We calculated n = 84 for each group using a two-sided T-test, and plan to include 100 patients in each group of the study, considering a potential drop-out rate of 15%. The patients will be randomized using the program Castor EDC. To prevent inequality in the study groups, at randomization patients will be stratified for their treatment before the study (dual therapy, MITT or SITT) and for inclusion during an exacerbation or during stable disease. The data will be analyzed using both the intention-to-treat (primary analysis) and per-protocol methods. The Kruskal–Wallis test or ANOVA, as appropriate, will be used to compare the average adherence between the three study groups. Post-hoc comparisons will be performed using Mann–Whitney U tests or Tukey’s HSD, as appropriate. The average baseline scores of the PROMs and baseline clinical status (FEV 1 , number of exacerbations, hospitalizations and rescue medication use) will be presented descriptively. These scores and outcomes are all continuous, unpaired data and will be compared between more than two groups. Therefore, we will use the Kruskal–Wallis or ANOVA, as appropriate, to investigate the differences between the three groups. The Net Promoter score is a binary variable, so we will use the Chi-square test. Questionnaire data will be analysed by both the difference in mean scores between groups and the percentage of patients achieving the minimally clinical important difference (MCID) when available. Furthermore, a mixed model repeated measurement analysis will be performed to assess the differences in the previously mentioned outcomes over time. The analysis will be conducted on normally distributed data, with or without transformations. The main parameter of interest is the group * time interaction. Between-group comparisons will be adjusted using the method of Sidak. If the data cannot be normalized, difference scores will be calculated (follow-up – baseline). These differences will be analysed using either the Kruskal–Wallis test or ANOVA, where appropriate. Post-hoc comparisons will be conducted using Mann–Whitney U tests or Tukey’s HSD, where appropriate.
Serious adverse events (SAEs) will be monitored and reported in accordance with the legal requirements and deadlines. The Ethics committee has granted permission for hospital admissions resulting from a COPD exacerbation not to be reported as SAE. This exemption is due to their frequent occurrence in this specific population. Instead, to monitor this fragile population, a Data and Safety Monitoring Board (DSMB) has been established. The DSMB will periodically review mortality rates, serious adverse events, and premature withdrawals from the study every six months. The application and e-health platform in use have a substantial history, spanning many years. Over the past two decades, 26 peer-reviewed scientific publications have been published. Notably, there have been no reported safety concerns, and assessments of usability, feasibility, and efficacy consistently yield positive results [ 43 ].
Non-adherence is a significant challenge in COPD patients, and addressing this issue is receiving increased attention. The first solution we investigated was simplifying the treatment by prescribing single-inhaler triple therapy (SITT) as an alternative to multi-inhaler triple therapy (MITT). The GOLD report 2023 suggested, for the first time, that single inhaler therapy may be more convenient than multi inhaler therapy [ 1 ]. However, although our literature review reveals some promising results regarding the effect of SITT on adherence, the quality of evidence is limited due to the absence of randomized controlled trials that specifically examined the difference in adherence between SITT and MITT. Due to the observational setting and design of all studies in the first part of this review, the SITT and MITT groups showed differences in their baseline characteristics, including the number of exacerbations prior to enrolment, disease severity, and FEV-1. Moreover, the quality of the observational data was occasionally limited. For example, two studies relied on administrative databases using health insurance claims [ 25 , 29 ]. Consequently, from these trials we are unable to draw conclusions on the cause-effect relationship between improved adherence and clinical outcomes. In contrast to the four studies included in our review, which all demonstrated slightly better clinical outcomes in SITT users, other literature, not incorporated into our review due to a lack of adherence as an outcome, presented contrasting results regarding the effect of SITT on clinical outcomes. Specifically, a retrospective study in Spain and an RCT showed improved clinical outcomes in SITT users [ 44 , 45 ]. However, three randomized controlled trials indicated that both SITT and MITT users exhibited similar results in terms of lung function, health status, exacerbation rate, and rescue medication usage [ 2 , 46 , 47 ].
The use of smart inhalers was the second potential solution to non-adherence that we investigated. Our review showed that while the effect on adherence was mostly positive, no consistent differences in clinical outcomes were observed. The strength of studies showing improved adherence in the absence of improved clinical outcomes is limited. These findings are consistent with other recent reviews in both COPD and asthma [ 18 , 20 , 21 ]. Demonstrating the connection between adherence and clinical outcomes has proven to be challenging. Given that COPD entails irreversible lung damage and the medication aims to stabilize rather than cure the disease, an extensive follow-up period is essential to demonstrate its impact on clinical outcomes. However, the current studies have limitations regarding the duration of follow-up. The smart inhalers used, as well as the supplementary interventions, and the extent of monitoring and/or interference varied significantly among the studies. The majority of smart inhalers used in current literature can only record the time and location of actuation. They are unable to measure whether inhalation is performed correctly. Other techniques, such as smart inhalers capable of measuring airflow or hair analysis of inhaled drugs, can assist in addressing this limitation. Further research is needed to gain a deeper understanding of the contributions of the different electronic modalities, the underlying mechanisms, clinical outcomes, and optimal implementation of these devices in clinical practice. Several challenges must be addressed before integrating smart inhalers into daily practice, including technical complexities, limited evidence concerning clinical outcomes, uncertainties about cost-effectiveness, and the issue of funding for the devices [ 18 ]. The TRICOLON study aims to offer additional evidence, potentially bringing us closer to their use in daily practice.
To the best of our knowledge, the TRICOLON trial is the first that aims to investigate whether single inhaler usage in COPD patients receiving triple therapy can improve adherence in a large-scale, randomized, controlled, real-world setting. Moreover, unlike the majority of existing studies focusing on the impact of smart inhalers, the TRICOLON trial distinguishes itself with a prolonged follow-up period of one year. We acknowledge that patients’ adherence may be influenced by their awareness of participating in a study. To minimize this interference, we have limited the number of study visits to closely resemble real-world settings. Additionally, patients are informed that the focus of this study is on the convenience of various treatment options, and adherence is not specifically mentioned in the information provided by the researchers or in the patient information letter. This has been approved by the Medical Ethical Review Board. The Tricolon study not only investigates the impacts of a single inhaler and the use of a smart inhaler on adherence but also evaluates various clinical outcomes, including exacerbation rates, hospitalizations, and disease burden. Nevertheless, the study is powered on the primary outcome adherence to inhalation therapy. Therefore, although not powered for the clinical outcomes or for the correlation between adherence and clinical outcomes, valuable information on these outcomes will be collected to inform possible follow-up studies.
The implementation of an e-health application may present challenges, whether due to technical issues or the potential unfamiliarity among patients and healthcare professionals [ 48 ]. To proactively address these concerns, we dedicated time to thoroughly test the application before the start of the study. This involved multiple stakeholders, including the researchers, the app producer, and patients. Moreover, the application's design is intentionally kept simple and clear, ensuring that individuals of all ages, educational backgrounds, and health literacy levels can easily comprehend and use it. This was confirmed in a previous study where an older, and thus more digitally challenged, population of patients with Idiopathic Pulmonary Fibrosis (IPF) used this app for daily spirometry. The study found that 80% of the participants found the app easy to use, and 90% did not perceive it as burdensome [ 49 ].
Beyond addressing the primary research questions, this TRICOLON study creates an opportunity for a direct comparison between three methods to measure adherence: digital data from the smart inhaler, self-reported data collected through the TAI questionnaire, and drug deposition data in hair. The use of this final technique is relatively uncommon in studies concerning inhalation medication, although it has been used in previous research related to cortisol and in forensic studies [ 22 , 50 ]. In a specific study involving asthma and COPD patients, the measurement of inhalation medication demonstrated a clear dose–response relationship among those using formoterol [ 41 ].
Our identification of a lack of high-quality data on the improvement of adherence of SITT over MITT therapy in COPD and limited data for smart inhalers highlights the need for further research. The multi-centre, randomized controlled, three-arm, real-world TRICOLON trial aims to increase insight in the value of SITT and the added value of electronic adherence monitoring.
All data relevant to the study are included in the article or uploaded as supplementary information. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Global Initiative for Chronic Obstructive Lung Disease. 2023 Report: global strategy for prevention, diagnosis and management of COPD [Available from: https://goldcopd.org/2023-gold-report-2/ .
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–29.
Article CAS PubMed Google Scholar
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671–80.
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–84.
Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–73.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–58.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020;201(12):1508–16.
Article PubMed PubMed Central Google Scholar
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35–48.
Bhattarai B, Walpola R, Mey A, Anoopkumar-Dukie S, Khan S. Barriers and strategies for improving medication adherence among people living with COPD: a systematic review. Respir Care. 2020;65(11):1738–50.
Article PubMed Google Scholar
van Boven JF, Chavannes NH, van der Molen T, Rutten-van Molken MP, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108(1):103–13.
Cushen B, Sulaiman I, Greene G, MacHale E, Mokoka M, Reilly RB, et al. The clinical impact of different adherence behaviors in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(12):1630–3.
Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.
Vrijens B, Dima AL, Van Ganse E, van Boven JF, Eakin MN, Foster JM, et al. What we mean when we talk about adherence in respiratory medicine. J Allergy Clin Immunol Pract. 2016;4(5):802–12.
George J, Kong DC, Stewart K. Adherence to disease management programs in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2007;2(3):253–62.
PubMed PubMed Central Google Scholar
Plaza V, Fernandez-Rodriguez C, Melero C, Cosio BG, Entrenas LM, de Llano LP, et al. Validation of the “Test of the Adherence to Inhalers” (TAI) for Asthma and COPD Patients. J Aerosol Med Pulm Drug Deliv. 2016;29(2):142–52.
Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: Myth and reality. Respir Med. 2017;129:117–23.
Loucks J, Zuckerman AD, Berni A, Saulles A, Thomas G, Alonzo A. Proportion of days covered as a measure of medication adherence. Am J Health Syst Pharm. 2022;79(6):492–6.
Jansen EM, van de Hei SJ, Dierick BJH, Kerstjens HAM, Kocks JWH, van Boven JFM. Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers. J Thorac Dis. 2021;13(6):3846–64.
O’Dwyer S, Greene G, MacHale E, Cushen B, Sulaiman I, Boland F, et al. Personalized biofeedback on inhaler adherence and technique by community pharmacists: a cluster randomized clinical trial. J Allergy Clin Immunol Pract. 2020;8(2):635–44.
Garin N, Zarate-Tamames B, Gras-Martin L, Milà R, Crespo-Lessmann A, Curto E, Hernandez M, Mestres C, Plaza V. Clinical Impact of Electronic Monitoring Devices of Inhalers in Adults with Asthma or COPD: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel). 2023;16(3):414. https://doi.org/10.3390/ph16030414 .
Schulte MHJ, Aardoom JJ, Loheide-Niesmann L, Verstraete LLL, Ossebaard HC, Riper H. Effectiveness of eHealth Interventions in Improving Medication Adherence for Patients With Chronic Obstructive Pulmonary Disease or Asthma: Systematic Review. J Med Internet Res. 2021;23(7):e29475.
Rygaard K, Linnet K, Johansen SS. A Systematic Review of Metabolite-to-Drug Ratios of Pharmaceuticals in Hair for Forensic Investigations. Metabolites. 2021;11(10):686. https://doi.org/10.3390/metabo11100686 .
Lin L, Liu C, Cheng W, Song Q, Zeng Y, Li X, et al. Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China. Front Pharmacol. 2023;14:1147985.
Article CAS PubMed PubMed Central Google Scholar
Halpin DMG, Rothnie KJ, Banks V, Czira A, Compton C, Wood R, et al. Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis. 2022;17:2417–29.
Mannino D, Bogart M, Wu B, Germain G, Laliberte F, MacKnight SD, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study. Respir Med. 2022;197:106807.
Deslee G, Fabry-Vendrand C, Poccardi N, Thabut G, Eteve Pitsaer C, Coriat A, Renaudat C, Maguire A, Pinto T. Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study). BMJ Open Respir Res. 2023;10(1):e001585. https://doi.org/10.1136/bmjresp-2022-001585 .
Gessner C, Trinkmann F, Bahari Javan S, Hovelmann R, Bogoevska V, Georges G, et al. Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany - The TriOptimize Study. Int J Chron Obstruct Pulmon Dis. 2022;17:3019–31.
Brusselle G, Himpe U, Fievez P, Leys M, Perez Bogerd S, Peche R, et al. Evolving to a single inhaler extrafine LABA/LAMA/ICS - Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE). Respir Med. 2023;218:107368.
Bogart M, Bengtson LGS, Johnson MG, Bunner SH, Gronroos NN, DiRocco KK. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States. Int J Chron Obstruct Pulmon Dis. 2024;19:97–110.
Beeh KM, Scheithe K, Schmutzler H, Kruger S. Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial. Int J Chron Obstruct Pulmon Dis. 2024;19:205–16.
Hesso I, Nabhani-Gebara S, Kayyali R. Objective Assessment of Adherence and Inhaler Technique among Asthma and COPD Patients in London: A Study in Community Pharmacies Using an Electronic Monitoring Device. Pharmacy (Basel). 2023;11(3):94. https://doi.org/10.3390/pharmacy11030094 .
Criner GJ, Cole T, Hahn KA, Kastango K, Eudicone J, Gilbert I. The Impact of Budesonide/Formoterol pMDI Medication Reminders on Adherence in Chronic Obstructive Pulmonary Disease (COPD) Patients: Results of a Randomized, Phase 4, Clinical Study. Int J Chron Obstruct Pulmon Dis. 2021;16:563–77.
Dierick BJH, Been-Buck S, Klemmeier T, Hagedoorn P, van de Hei SJ, Kerstjens HAM, et al. Digital spacer data driven COPD inhaler adherence education: The OUTERSPACE proof-of-concept study. Respir Med. 2022;201:106940.
Kaye L, Gondalia R, Thompson A, Stempel DA, Barrett MA. The relationship between objective app engagement and medication adherence in asthma and COPD: a retrospective analysis. Sci Rep. 2021;11(1):24343.
Yawn BP, McCreary GM, Linnell JA, Pasquale CB, Malanga E, Choate R, et al. Pilot Study of a Patient Experience with an ELLIPTA Inhaler electronic medication monitor and associated integrated system: a prospective observational study using the COPD Patient-Powered Research Network. Chronic Obstr Pulm Dis. 2021;8(4):488–501.
Kaye L, Gondalia R, Barrett MA, Williams M, Stempel DA. Concurrent improvement observed in patient-reported burden and sensor-collected medication use among patients enrolled in a COPD Digital Health Program. Front Digit Health. 2021;3:624261.
Gregoriano C, Dieterle T, Breitenstein AL, Durr S, Baum A, Giezendanner S, et al. Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial. Respir Res. 2019;20(1):273.
Broadbent E, Garrett J, Jepsen N, Li Ogilvie V, Ahn HS, Robinson H, et al. Using Robots at Home to Support Patients With Chronic Obstructive Pulmonary Disease: Pilot Randomized Controlled Trial. J Med Internet Res. 2018;20(2):e45.
Alshabani K, Attaway AA, Smith MJ, Majumdar U, Rice R, Han X, et al. Electronic inhaler monitoring and healthcare utilization in chronic obstructive pulmonary disease. J Telemed Telecare. 2020;26(7–8):495–503.
Nides MA, Tashkin DP, Simmons MS, Wise RA, Li VC, Rand CS. Improving inhaler adherence in a clinical trial through the use of the nebulizer chronolog. Chest. 1993;104(2):501–7.
Hassall D, Brealey N, Wright W, Hughes S, West A, Ravindranath R, et al. Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD. Pulm Pharmacol Ther. 2018;51:59–64.
Cooper GA, Kronstrand R, Kintz P, Society of Hair T. Society of Hair Testing guidelines for drug testing in hair. Forensic Sci Int. 2012;218(1–3):20–4.
https://www.gezondheidsmeter.nl/site/index.php [
Alcazar-Navarrete B, Jamart L, Sanchez-Covisa J, Juarez M, Graefenhain R, Sicras-Mainar A. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain. Chest. 2022;162(5):1017–29.
Halpin DMG, Worsley S, Ismaila AS, Beeh KM, Midwinter D, Kocks JWH, Irving E, Marin JM, Martin N, Tabberer M, Snowise NG, Compton C. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021;7(2):00950–2020. https://doi.org/10.1183/23120541.00950-2020 .
Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131.
Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19(1):19.
Pinnock H, Hui CY, van Boven JFM. Implementation of digital home monitoring and management of respiratory disease. Curr Opin Pulm Med. 2023;29(4):302–12.
Moor CC, Wapenaar M, Miedema JR, Geelhoed JJM, Chandoesing PP, Wijsenbeek MS. A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers. Respir Res. 2018;19(1):105.
Greff MJE, Levine JM, Abuzgaia AM, Elzagallaai AA, Rieder MJ, van Uum SHM. Hair cortisol analysis: An update on methodological considerations and clinical applications. Clin Biochem. 2019;63:1–9.
Download references
We appreciate the assistance of Carmen van der Heijden, librarian at the Medical Library in the Franciscus Gasthuis & Vlietland hospital, in conducting the PubMed searches. We would like to thank the members of the investigational teams across all participating hospitals for their dedicated time and effort in conducting this study.
TRICOLON study group
The TRICOLON Study Group consortium consists of the individuals listed below:
Liz J.A. Cuperus MD 1,2,3 , Job van der Palen PhD 4 , Arnoud Aldenkamp MD 5 , Astrid van Huisstede MD PhD 6 , Erik W.M.A. Bischoff MD PhD 7 , Job F.M. van Boven PharmD PhD 8 , Folkert Brijker MD 9 , Stephan Dik MD 10 , Jeroen A.J.M. van Excel MD 11 , Martijn Goosens MD 12 , Peter Th.W. van Hal MD PhD 13 , Jolanda C. Kuijvenhoven MD PhD 14 , Lisette I.Z. Kunz MD PhD 15 , Erwin C. Vasbinder PhD 16 , Huib A.M. Kerstjens MD PhD 2 , Johannes C.C.M. in ’t Veen MD PhD 1,3 , Marjo van der Poel 17 , Marijke Amelink 9 , Anke Rol 18 , Jennifer de Graaf 18 , Petra Hirmann 19 , Fleur van Tour 20 , Elly Jordens 13 , Lydia Alfing 13 , Gerda Lenderink 21 , Thecla Rupert 21 , Truus Rietveld 21 , Jasmijn van Campen 15 , Jantine de Bruijn 15 , Janice van ter Burg 15 , Walter van Litsenburg 5 , Len Knoops 22 , Margot Eggermont-Schilt 23 , Manon de Waard-Heijligers 23 , Ilonka Paalvast-Schouten 23 , Sarah van Oord 11
1 Pulmonology Department, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands
2 Pulmonology Department, University of Groningen, University Medical Center Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands
3 Pulmonology Department, Erasmus Medical Centre, Rotterdam, the Netherlands
4 Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands
5 Department of Pulmonary Medicine, Catharina Hospital, Eindhoven, The Netherlands
6 Department of Pulmonology, Northwest Clinics, Alkmaar, the Netherlands
7 Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, Netherlands
8 Department of Clinical Pharmacy & Pharmacology Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
9 Department of Pulmonary Medicine, Spaarne Gasthuis, Haarlem, The Netherlands
10 Department of Pulmonary Medicine, Albert Schweitzer ziekenhuis, Dordrecht, The Netherlands
11 Department of Pulmonary Medicine, HagaZiekenhuis, The Hague, The Netherlands
12 Department of Pulmonary Medicine, Gelre Ziekenhuizen, Zutphen, The Netherlands
13 Department of Respiratory Medicine, Van Weel-Bethesda Hospital, Dirksland, the Netherlands
14 Department of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands
15 Department of Pulmonology, Haaglanden Medical Centre, The Hague, the Netherlands
16 Department of Clinical Pharmacy, Franciscus Gasthuis, Rotterdam, the Netherlands
17 Spaarne Gasthuis, Haarlem, The Netherlands
18 Northwest Clinics, Alkmaar, the Netherlands
19 Medical Centre Leeuwarden, Leeuwarden, the Netherlands
20 Albert Schweitzer ziekenhuis, Dordrecht, The Netherlands
21 Gelre Ziekenhuizen, Zutphen, The Netherlands
22 Catharina Hospital, Eindhoven, The Netherlands
23 HagaZiekenhuis, The Hague, The Netherlands
The faculty received an unrestricted grant from Chiesi Pharmaceuticals B.V. Furthermore, the funding includes contributions from the research group in the Franciscus Gasthuis & Vlietland hospital and transformation funds from health insurance companies.
Authors and affiliations.
Pulmonology Department, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands
Liz J. A. Cuperus & Johannes C. C. M. in ’t Veen
Pulmonology Department, University of Groningen, University Medical Center Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands
Liz J. A. Cuperus & Huib A. M. Kerstjens
Pulmonology Department, Erasmus Medical Centre, Rotterdam, the Netherlands
Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands
Job van der Palen
Department of Pulmonary Medicine, Catharina Hospital, Eindhoven, The Netherlands
Arnoud Aldenkamp
Department of Pulmonology, Northwest Clinics, Alkmaar, the Netherlands
Astrid van Huisstede
Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands
Erik W. M. A. Bischoff
Department of Clinical Pharmacy & Pharmacology Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Job F. M. van Boven
Department of Pulmonary Medicine, Spaarne Gasthuis, Haarlem, The Netherlands
Folkert Brijker
Department of Pulmonary Medicine, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands
Stephan Dik
Department of Pulmonary Medicine, HagaZiekenhuis, The Hague, The Netherlands
Jeroen A. J. M. van Excel
Department of Pulmonary Medicine, Gelre Ziekenhuizen, Zutphen, The Netherlands
Martijn Goosens
Department of Respiratory Medicine, Van Weel-Bethesda Hospital, Dirksland, The Netherlands
Peter Th. W. van Hal
Department of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
Jolanda C. Kuijvenhoven
Department of Pulmonology, Haaglanden Medical Centre, The Hague, The Netherlands
Lisette I. Z. Kunz
Department of Clinical Pharmacy, Franciscus Gasthuis, Rotterdam, The Netherlands
Erwin C. Vasbinder
You can also search for this author in PubMed Google Scholar
LC and JV conducted the assessment and selection of articles from the PubMed searches, HK was consulted in case of author disagreements. JV initiated the Tricolon trial and acquired the funding. LC, JV, HK, JvdP, EB, JvB were involved in the study design and protocol. LC is the coordinating investigator, JV is the principal investigator. LC, JV and HK wrote the main manuscript text. All authors have thoroughly read, critically revised, and approved the submitted version of the final manuscript.
Correspondence to Liz J. A. Cuperus .
Ethics approval and consent to participate.
Ethics approval for the Tricolon study was waived by the Medical research Ethics Committees United (NL79938.100.22). This study is performed after approval by the Institutional Research Board and Board of Directors of the participating hospitals. The study is registered at clinicaltrials.gov (NCT05495698). Informed consent was obtained from all subjects.
Not Applicable.
JvdP: none.
EB: unrestricted grants and speaking fees received from Chiesi Pharmaceuticals B.V., Boehringer Ingelheim bv, GlaxoSmithKline.
JvB: received unrestricted research grants from Aardex, AstraZeneca, Chiesi, European Commission COST Action 19132 (ENABLE), European Respiratory Society CRC “CONNECT”, Novartis, Pfizer, Pill Connect, Trudell Medical and consultancy/speaker fees from AstraZeneca, Chiesi, GSK, Novartis, Teva and Vertex. All payments were unrelated to this manuscript and all paid to his institution (UMCG).
LK: received speaker fees from AZ.
EV: received unrestricted research grants from AstraZeneca and Pfizer.
HK: reports grants and consultancy/advisory board participation from/for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Novartis, all outside the submitted work. All were paid to his institution.
JiV: received unrestricted faculty research grants from GSK, Teva, AZ, Chiesi, Sanofi, and speaker fees from AZ, GSK, Sanofi, Chiesi, Stichting RoLeX and Health Investment.
Publisher’s note.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Suuplementary material 1., rights and permissions.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Reprints and permissions
Cite this article.
Cuperus, L.J.A., van der Palen, J., Aldenkamp, A. et al. Adherence to single inhaler triple therapy and digital inhalers in Chronic Obstructive Pulmonary Disease: a literature review and protocol for a randomized controlled trial (TRICOLON study). BMC Pulm Med 24 , 317 (2024). https://doi.org/10.1186/s12890-024-03044-3
Download citation
Received : 16 February 2024
Accepted : 02 May 2024
Published : 04 July 2024
DOI : https://doi.org/10.1186/s12890-024-03044-3
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
ISSN: 1471-2466
BMC Medical Education volume 24 , Article number: 720 ( 2024 ) Cite this article
213 Accesses
Metrics details
As healthcare systems rapidly become more complex, healthcare leaders are navigating expanding role scopes and increasingly varied tasks to ensure the provision of high-quality patient care. Despite a range of leadership theories, models, and training curricula to guide leadership development, the roles and competencies required by leaders in the context of emerging healthcare challenges (e.g., disruptive technologies, ageing populations, and burnt-out workforces) have not been sufficiently well conceptualized. This scoping review aimed to examine these roles and competencies through a deep dive into the contemporary academic and targeted gray literature on future trends in healthcare leadership roles and competencies.
Three electronic databases (Business Source Premier, Medline, and Embase) were searched from January 2018 to February 2023 for peer-reviewed literature on key future trends in leadership roles and competencies. Websites of reputable healthcare- and leadership-focused organizations were also searched. Data were analyzed using descriptive statistics and thematic analysis to explore both the range and depth of literature and the key concepts underlying leadership roles and competencies.
From an initial 348 articles identified in the literature and screened for relevance, 39 articles were included in data synthesis. Future leadership roles and competencies were related to four key themes: innovation and adaptation (e.g., flexibility and vision setting), collaboration and communication (e.g., relationship and trust building), self-development and self-awareness (e.g., experiential learning and self-examination), and consumer and community focus (e.g., public health messaging). In each of these areas, a broad range of strategies and approaches contributed to effective leadership under conditions of growing complexity, and a diverse array of contexts and situations for which these roles and competencies are applicable.
This research highlights the inherent interdependence of leadership requirements and health system complexity. Rather than as sets of roles and competencies, effective healthcare leadership might be better conceptualized as a set of broad goals to pursue that include fostering collaboration amongst stakeholders, building cultures of capacity, and continuously innovating for improved quality of care.
Peer Review reports
Healthcare leadership has grown in scope and importance in response to the increasing complexity of healthcare delivery [ 1 ]. Healthcare systems have become increasingly multifaceted, delivering a vast array of services across multiple levels, from preventative and primary care to acute, specialized care, and long-term care, to address the care needs of a changing population [ 1 ]. As populations age, chronic diseases rise, and the epidemiology and demographics of disease shift, new models of care rapidly emerge to address the ever-expanding spectrum of patient needs [ 2 ]. Advancements in technologies, tests and treatments and personalized medicine come with regulatory and ethical implications, and a growth in workforce specializations [ 3 , 4 ]. Healthcare leaders are navigating evermore complex webs of actors in the system – doctors, nurses, technicians, administrators, insurers, and patients – striving to balance priorities, foster collaboration, and provide strategic direction toward high-quality and safe patient care [ 5 ]. At the same time as running complex services, healthcare leaders need to continually assess, implement, and govern new technologies and services, adhere to the latest regulations and guidelines, operate within the confines of budgetary allocations, and meet growing consumer expectations for affordable and accessible care [ 6 , 7 ].
Competent healthcare leadership is widely considered to be critical for improving patient safety, system performance, and the effectiveness of healthcare teams [ 8 , 9 , 10 ]. Leadership has been identified as a key shaping influence on organizational culture [ 11 ], including workplace commitment to safety [ 12 ], and on preventing workforce burnout [ 13 , 14 ]. The increased need for multidisciplinary and integrated care models has shed growing light on the leadership roles of clinicians, including physicians, nurses, and allied health practitioners [ 15 , 16 , 17 ]. Individuals with both clinical and leadership expertise have been considered vital in complex healthcare landscapes because of their ability to balance administrative needs while prioritizing safety and high-quality care provision [ 18 , 19 , 20 , 21 , 22 ]. For example, physician leaders, through their deep understanding of clinical care and their credibility and influence, have been considered best able to devise strategies that improve patient care amidst stringent financial conditions [ 23 , 24 , 25 , 26 ]. Clinical leaders, particularly physician leaders, might also be of key importance for facilitating the success of collaborative care and care integration [ 27 ].
The formalization of healthcare leadership emerged as the importance of specialized healthcare leadership skills became increasingly needed, recognized and understood [ 1 , 28 , 29 ]. Leadership in healthcare has been conceptualized in several different ways, and a multitude of theories, frameworks, and models have been proposed to explain leadership roles and responsibilities [ 30 , 31 , 32 , 33 ]. For example, the CanMEDS Framework describes the Leader Role of physicians, which is comprised of key and enabling competencies, tasks, and abilities [ 34 , 35 ], and adaptations to this Framework emphasize the varying roles that leadership comprises and the competencies that fulfill them [ 36 ]. Although these frameworks present a good starting point for articulating leadership role scopes and their associated competencies, many fall short in explaining how leaders navigate complex, dynamic, multi-dimensional, and highly variable healthcare systems [ 37 ]. This is becoming increasingly recognized; CanMEDS is due to be updated in 2025 to incorporate competencies related to complexity [ 38 ]. Meanwhile, on the front lines, lack of role clarity and ambiguity about tasks and responsibilities presents a significant barrier for healthcare leaders [ 1 , 15 ]. In complex and unpredictable systems like healthcare, leaders spend substantial time ‘sense-making’, understanding, prioritizing and responding adaptively according to the needs of the situation [ 39 , 40 ]. The latest research on future healthcare trends tells us that increasing complexity associated with digital innovation, healthcare costs, regulatory compliance, sustainability concerns and equitable resource distribution will pose challenges to all actors in health systems [ 41 , 42 , 43 , 44 , 45 ]. In the face of these emerging challenges, it is vital to understand the range and type of roles and competencies that leaders will need to fulfil in the imminent future.
The aim of this scoping review is to examine the literature on the key trends in roles and competencies required for healthcare leaders in the future. We conceptualized ‘competencies’ as the attributes, skills, and abilities that comprise the fulfilment of varying leadership roles, as informed by the CanMEDS Framework [ 34 , 36 ]. Scoping review methodology was utilized to capture a broad range of literature types and identify key themes or groupings of future trends in leadership roles and competencies. Rather than focusing on answering specific questions (as per previous systematic reviews on leadership [ 46 , 47 ]) or developing theory (by utilizing a theoretical review approach to leadership literature [ 48 , 49 ]), we sought to map and identify patterns and trends within the leadership literature [ 50 ]. To investigate trends in leadership roles and competencies, we targeted emerging perspectives from key reputable thought leaders to supplement academic research [ 51 , 52 ].
The conduct and reporting of this review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines [ 53 ].
Comprehensive search strategies were developed, adapting search strategies utilized in a previous systematic review on physician leadership [ 26 ], and receiving input and expertise from two clinical librarians at Macquarie University (see supplementary file 1 for database search strategies). Medline, Embase, and Business Source Premier were searched from January 2018 to February 2023 to enable meaningful inferences to be made about future trends based on current perspectives. To capture key trends, patterns, shifts, and forecast changes to healthcare leadership, the Medline database search was limited to the ‘Trends’ subheading, “ used for the manner in which a subject changes, qualitatively or quantitatively, with time, whether past, present, or future. Includes “forecasting” & “futurology" ” (see supplementary file 1 ) [ 54 ]. For Embase and Business Source Premier, the ‘Trends’ subheading was not available, and instead key search terms were included to capture future trends, including “predict*”, “forecast*”, “shift*” and “transform*”. Efforts were made to locate texts that could not be retrieved, by searching Macquarie University’s digital library records and contacting authors to request the full text.
To complement the database searches, targeted searches of the Faculty of Medical Leadership and Management (FMLM; UK) website and The King’s Fund (UK) website were undertaken to identify emerging perspectives on the future roles and requirements of healthcare leaders. Targeted website searches can aid in uncovering unpublished yet relevant research identified by advocacy organizations or subject specialists, and research potentially missed by database searches [ 52 , 55 ]. Key search terms entered into the websites included ‘future healthcare’, ‘medical leader’, ‘clinical leader’, ‘medical manager’, ‘physician executive’, and ‘education and training’. We included articles that focused on leaders with a clinical background and leaders without a clinical background, to provide a comprehensive overview of leadership roles and requirements of reference to health systems [ 26 ].
Database literature search.
References were uploaded into online data management software Rayyan [ 56 ], and duplicate records were identified and removed. Titles and abstracts of results were screened by three team members (SS, EL, RP) according to the inclusion and exclusion criteria (Table 1 ). Articles were included if they focused on future trends in the roles, competencies, attributes, or requirements of healthcare leaders, and if they reported on countries within the Organization for Economic Co-operation and Development (OECD). We limited our search to OECD countries to maximize the generalizability of findings within a developed context and enable meaningful trends to be identified. A subset of the articles was screened by all three team members to ensure that decisions were being made in a standardized manner. After this article subset was screened, the three team members discussed screening decisions, and disagreements were resolved by consensus or through discussion with JB [ 57 ]. During this process, two further exclusion criteria (#4 and #5, Table 1 ) were added to ensure that the screening process adhered to the aim of the current review. We excluded articles that focused on theories and definitions of leadership (e.g., for the purpose of developing educational or professional frameworks) without highlighting trends or changes in roles and competencies for future leadership. We also excluded articles that focused on healthcare interventions in which leaders may have been participants, but their roles or competencies were not the focus. Articles included at title and abstract screening were independently read in full and assessed for eligibility. Disagreements about inclusion were resolved through discussion, with JB available for arbitration if necessary. It was determined at this stage that if articles were conference abstracts in which the full presentation could not be accessed, the article of focus was sought and included in the analysis.
References were screened according to the inclusion and exclusion criteria (Table 1 ), except that articles only needed to report (rather than focus) on future leadership roles and requirements. This is because we wanted to ensure that our analysis broadly captured the most recent sources of information on healthcare leadership requirements, even if these sources did not focus exclusively on leadership.
Data from all records were appraised and charted simultaneously using a purpose-designed Excel data charting form designed by SS (and subsequently reviewed and endorsed by RP and EL). Multimedia records arising from targeted gray literature searches were listened to and transcribed by RP and checked by SS. Extracted data included article details (authors, year, country, text type), leadership focus (training or educational approaches, styles of leadership), and major and minor themes. Database literature were extracted first to identify and develop themes, and the targeted gray literature were extracted second to extend and embellish those themes.
Data from included articles were synthesized according to the Arksey and O’Malley framework for scoping reviews, selected for its detailed guidance on data collation, synthesis, and presentation [ 58 ]. The breadth, range, and type of data were analyzed using descriptive statistics, and underlying groups of leadership roles and competencies were analyzed using thematic analysis. First, the authorship team familiarized themselves with the articles to gain a broad overview of contexts in which leadership was discussed. An inductive approach was used to identify emerging themes of leadership roles and competencies in the database literature, where common concepts were identified, coded, and grouped together to form themes. Team discussion facilitated the final set of themes that were interpreted from the data. During this process, the extracted data were compared to the codes, groups, and resultant themes to examine the degree of consistency between the data and the interpreted findings. Where inconsistencies were identified, suggested changes (e.g., to code labels or groupings) were compared, and the most appropriate changes adopted. Targeted gray literature sources were deductively analyzed according to the identified themes.
Figure 1 displays the process of identification and screening of included studies. Database searches yielded 160 records, from which 11 duplicates were removed. The remaining 149 database records were screened by title and abstract, after which a further 114 records were excluded. Of the remaining 35 that were assessed for eligibility, 22 were excluded, and 13 were included in the current review. Targeted gray literature searches yielded an additional 188 records, from which 146 were identified as duplicates and removed. The remaining 42 records were read in full and assessed for eligibility, from which a further 16 were excluded, and 26 were included in the current review. In total, 39 records were retained and synthesized.
PRISMA flowchart displaying the process of identification and selection of included articles
The characteristics of the included records are displayed in Tables 2 and 3 . Of the database literature, most articles were published in the USA ( n = 11), and the remaining two articles were published in Canada and Australia. Seven articles were empirical; three studies employed qualitative methods [ 59 , 60 , 61 ], three were quantitative [ 62 , 63 , 64 ], and one mixed methods [ 65 ]. Six articles were non-empirical; three were perspective pieces [ 66 , 67 , 68 ], and three were reports on training or organizational interventions [ 69 , 70 , 71 ]. Of the targeted literature, blog-type articles were most common ( n = 11) [ 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ], followed by news articles ( n = 5) [ 83 , 84 , 85 , 86 , 87 ], reports ( n = 4) [ 88 , 89 , 90 , 91 ], editorials ( n = 2) [ 92 , 93 ], podcasts ( n = 2) [ 94 , 95 ], and video and interview transcripts ( n = 2) [ 96 , 97 ]. As targeted gray sources selected were The King’s Fund website and the FMLM website, the records from these websites were published in the UK.
All 13 articles derived from the database searches focused on innovation and adaptation in future leadership. Two empirical articles reported on the ways in which clinical and non-clinical leaders innovated during the COVID-19 pandemic, rapidly designing new models of hospital care [ 61 ] and extending their roles to encompass the implementation of virtual leadership [ 64 ]. Qualitative investigations explored the importance of entrepreneurial leadership for implementing clinical genomics [ 59 ] and key leadership attributes for practice-level innovation and sustainability [ 60 ]. Four articles examined leadership training approaches that build physicians’ capacity to understand, adapt to, and manage change, overcome resistance, and think entrepreneurially [ 62 , 63 , 65 , 70 ]. Two reports described the necessity for healthcare leaders to be able to create a shared vision for an organization; one highlighted the importance of leaders being confident and “self-propelled to intervene” [ 69 ], and one emphasized physician leaders’ credibility as a catalyst for change management among healthcare providers [ 71 ]. The latter report also identified that visible and committed leadership that is sensitive to workplace cultures is critical for the success of change management activities [ 71 ]. Three perspective pieces discussed increasing opportunities for medical and other clinical leaders to create positive change in increasingly complex healthcare landscapes and fulfill the demands of the industry and public [ 66 , 67 , 68 ].
In the targeted gray literature, 19 of 26 records (73%) focused on innovative and adaptive leadership. Records primarily explored adaptive leadership behaviors during COVID-19, such as service redesign, introducing improved flexibility, learning mechanisms, and support platforms [ 73 , 76 , 77 , 97 ], and future innovation to manage climate change impacts [ 81 ], growing inequities [ 89 ], and emerging technologies [ 75 , 83 , 94 , 96 ]. Comfort with change, vision setting, and a desire to innovate were emphasized as key leadership attributes for future healthcare [ 82 , 83 , 88 , 96 ]. Records also explored how to best train and develop leaders for transforming health systems, including the National Health Service (NHS) [ 84 , 90 , 96 ]. New leadership training structures were proposed that foster innovation and adaptability in leaders [ 80 , 90 , 96 ] and encourage flexibility for cross-disciplinary learning.
Collaboration and communication was a second theme that emerged across all 13 database articles. Three studies explored how collaborative leadership can foster innovation with regards to implementing genomics testing [ 59 ], creating new work models during COVID-19 [ 61 ] and developing new leadership styles via telecommunications [ 64 ]. Six articles focused on the importance of collaborating to build relationships across organisations [ 67 , 68 , 71 ] and within teams [ 65 , 69 , 70 ]. Three articles highlighted that effective communication contributes to organizational success, through fostering psychologically safe cultures [ 60 , 66 ] and generating the trust and rapport necessary for implementing technological innovations [ 71 ]. Two studies examined the impact of leadership training on physicians’ communication competencies [ 62 , 63 ].
In the targeted gray literature, 17 of 26 records (65%) focused on collaboration and communication. Records discussed specific initiatives to improve communication in clinical teams, such as staff surveys, daily huddles, and dedicated days for networking [ 75 , 77 , 80 , 95 ]. Cross-boundary collaboration and collective leadership (e.g., between clinicians and managers) [ 83 ] were advocated as a means to solve challenges [ 81 , 90 ], help build public trust [ 79 , 83 ], and improve quality of care [ 78 , 83 , 85 , 94 ]. Twelve records focused on the importance of team and leadership collaboration to create positive workplace cultures and improve staff wellbeing, through communication strategies such as openness and honesty [ 78 , 80 , 95 ], active listening and empathy [ 73 , 78 , 86 , 88 , 90 ], transparency [ 88 , 94 , 95 ], and inclusivity [ 85 , 94 ]. Three articles emphasized that encouraging staff autonomy, building trust, and demonstrating compassion facilitate better quality care than demanding and punitive leadership actions [ 73 , 74 , 88 ].
Nine of 13 database articles (69%) focused on a third theme, self-development and self-awareness in leadership. Four articles examined approaches to leadership development that incorporated self-development and self-awareness (e.g., personality testing) [ 63 , 65 , 69 , 70 ], with two articles describing these competencies as enablers for the development of other more advanced competencies (e.g., execution) [ 69 , 70 ]. Similar competencies explored included landscape awareness [ 60 ], self-organisation [ 60 ], emotional intelligence [ 64 ], and self-examination, the last of which was described as essential to gain skills beyond clinical roles [ 68 ], facilitate positive perceptions of others [ 66 ], and to remain relevant and effective in a changing healthcare environment [ 67 ]. One article also proposed strategies such as journaling, mindfulness, and feedback to encourage ongoing reflection on leadership decisions and biases [ 67 ].
In the targeted gray literature, seven of 26 records (27%) focused on self-development and self-awareness. Records examinedd the importance of continual personal leadership development, including mentoring and experiential learning, to facilitate understanding of one’s own skills [ 78 , 80 , 97 ]. Tools to facilitate self-reflection in physician leaders were advocated including the FMLM smartphone app [ 92 ] and leadership longitudinal assessments [ 91 ]. Self-care and resilience practices (e.g., meditation, social support) were also advocated for physician leaders as a means to manage “greater levels of stress and responsibility” [ 94 ].
Consumer engagement and advocacy was a fourth theme and a focus of nine targeted gray literature records (35%). Records discussed patient and community engagement as essential for health system improvement, and examples included involving patients in health service design [ 74 , 77 ], creating channels of ongoing dialogue [ 79 , 83 ] and building stronger health system-community relationships [ 79 , 88 ]. Two records described the importance of public health messaging in improving health literacy [ 83 ] and countering misinformation [ 86 ], and two focused on the role of leaders in advocating for social justice and striving to improve equitable outcomes [ 75 , 93 ].
This scoping review identified 39 key resources that explored future trends in healthcare leadership roles and competencies. These records were derived from a combination of academic and targeted gray literature searches, juxtaposed and synthesized to build understanding of leadership to improve health systems into the future. Four themes of competencies emerged from the findings – innovation and adaptation, communication and collaboration, self-development and self-awareness, and consumer engagement and advocacy.
The competencies of healthcare leaders given the most attention in the literature over the last five years relate to innovation and adaptability . Both the academic and targeted gray literature focused on how leaders, clinical and non-clinical, demonstrated innovativeness and adapted to the demands of COVID-19, including rethinking and redesigning systems to support staff and patients [ 64 , 77 ]. The second focus of the literature on innovation and adaptability was geared toward the development of these capacities in leaders through education and training, as well as through opportunities for leaders to actualize their skills [ 70 , 90 ]. The literature indicated that as the complexity of healthcare is accelerating, leaders must both understand, and have opportunities to demonstrate, innovation amidst dynamic, variable, and demanding environments [ 59 , 60 , 71 ]. This aligns with prior research demonstrating that innovation uptake requires strong change management, and the ability to rapidly assess, understand, and apply innovative changes (e.g., medical technologies) [ 1 , 98 ]. While innovations might improve the system’s ability to deal with complex challenges in the long-term, their implementation can be challenged by a number of moving parts – including workforce changes, new rules and regulations, fluctuating resources and new patient groups – which leaders must consider and appropriately plan for [ 99 , 100 ]. Perhaps an even greater challenge for leaders to overcome when embracing innovation is the tendency for growing complexity to lock the organization into suboptimal conditions (i.e., inertia) [ 101 ]. Building awareness of the interacting components of complex systems and the flexibility required for adaptation and resilience should be a key focus of healthcare leadership education and training [ 102 ].
Competencies associated with communication and collaboration have also been a focus of the healthcare leadership literature. Academic literature dealt primarily with how collaborative structures and behaviors can help leaders innovate and build organizational cultures geared for success [ 59 , 61 , 71 ]. Targeted gray literature focused on how leaders can foster communication within teams, and the positive impacts of an open and accountable culture on staff wellbeing and productivity [ 73 , 74 ]. These findings echo research on resilient health systems emphasizing that ‘over-managing’ restricts the adaptive capacities needed by teams within dynamic healthcare environments [ 100 , 103 ]. The literature pointed to the need for leaders to strengthen communication and collaboration at varying levels – environmental, team, and organizational – to enable more efficient and better-quality healthcare delivery, and during this process they should endeavor to model the balance between autonomy and accountability [ 104 ]. Implementing regular touchpoints that engage multiple stakeholders, such as communities of practice, can help to create positive feedback loops that enable systems change [ 105 ], and overcome organizational barriers to collaboration and information sharing, such as weak relationships and inadequate communication [ 106 , 107 ].
Self-development and self-awareness also emerged as an important aspect of leadership. Academic literature focused primarily on how these capacities are developed in leaders through structured education and training, including self-assessments and targeted educational modules [ 65 , 69 ]. Targeted gray literature discussed a range of activities outside of structured training (e.g., experiential learning) that can support leaders’ self-reflection and development, for physician leaders in particular to assess their performance and improve their leadership approaches [ 91 , 92 ]. These findings suggest that personal leadership development must go beyond formal curriculum requirements to incorporate everyday learning inputs [ 78 ], and align with other recent literature suggesting that self-regulation in leaders can be fostered through practicing self-discipline, boundary-setting, and managing disruptions, particularly in the digital age [ 108 , 109 ]. Practicing self-awareness can help leaders not only to sense-make in complex systems – to adapt to new situations and make appropriate trade-offs – but also to sense-give – to articulate and express the organization’s vision [ 40 ]. A minor theme, observed only in the targeted gray literature, was related to leaders’ roles and competencies in consumer engagement and advocacy . The importance of increasing consumer engagement in healthcare was emphasized, as well as the structures that are needed to facilitate these changes [ 79 ]. Working alongside consumers was highlighted as critical during times of changing care and need, such as during COVID-19 [ 77 , 86 ]. Although the involvement of consumers and the public in the co-production of care is increasing [ 110 ], there is limited academic literature focused on the roles of leaders in creating optimal environments for co-production. Consumer and community involvement in change efforts helps to improve care processes and outcomes [ 111 ], but leaders might face challenges understanding and operationalizing local engagement mechanisms [ 112 ]. Identifying the organizational and system levers that enable greater consumer involvement, and how leaders can advocate for these levers in their local context, is a fruitful area for future investigation.
The findings of the current review have implications for professional organizations that train healthcare leaders, such as the Australian College of Health Services Management (ACHSM) in Australia, and train clinicians to be leaders, including the UK’s FMLM. Creating a future-focused curriculum addressing the competencies related to the themes identified, in particular innovation and adaptability, is essential to prepare healthcare leaders for growing and changing scopes of responsibility. Such competencies are less amenable to formal theoretical teaching solely and require carefully crafted experiential learning programs in health settings, with supervision by experienced and effective healthcare leaders.
A notable strength of this scoping review was the inclusion of a broad range of sources and perspectives on the future of healthcare leadership. We captured empirical studies, theoretical academic contributions (e.g., commentaries from healthcare leaders), and targeted grey literature, which is often a more useful source of information on emerging topics [ 52 ]. As a result, our findings identified key future trends in the roles and competencies of leaders, both clinical and non-clinical, across a wide range of contexts and situations. Another strength of this review was its specific focus on contemporary literature that examined future trends in leadership, to inform how leaders can prepare for upcoming challenges, rather than focusing on leadership that was effective in the past.
There are limitations to this review. Our search strategies may not have adequately captured other leadership trends applicable across contemporary healthcare settings or those faced by leaders and teams on the front lines of care [ 113 ]. Incorporating search terms related to specific settings, as well as complex systems concepts, may have enabled greater inferences to be made about how unique future challenges require new approaches to the development of healthcare leaders. To scope future-focused research and perspectives, database searches were narrowly restricted, and it is likely that key articles were missed. Targeted gray literature searches represent key thought leaders in healthcare and leadership, and while this enabled relevant information to be efficiently collected, undertaking highly focused searches may have introduced bias associated with geographical area (i.e., the UK) and particular stakeholder groups (e.g., policy-makers) [ 55 ]. Our choice to limit the current review to studies reporting in OECD countries further limited generalizability to other settings including in low-income and middle-income countries (LMICs) [ 1 ].
The roles and competencies of leaders are deeply enmeshed in, and reflective of, a complex and continuously transforming healthcare system. This research highlights the types of roles and competencies important for leaders facing a myriad of challenges, and the range of contexts and situations in which these types of roles and competencies can be applied. The ways in which roles and competencies manifest is highly contextual, dependent on both role responsibilities and the situational demands of healthcare environments.
Data supporting these research findings are available upon reasonable request. Further inquiries can be directed to the corresponding author.
Faculty of Medical Leadership and Management
National Health Service
Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews
Royal Australasian College of Medical Administrators
United States of America
United Kingdom
Figueroa CA, Harrison R, Chauhan A, et al. Priorities and challenges for health leadership and workforce management globally: a rapid review. BMC Health Serv Res. 2019;19:1–11. https://doi.org/10.1186/s12913-019-4080-7
Article Google Scholar
Braithwaite J, Mannion R, Matsuyama Y, et al. The future of health systems to 2030: a roadmap for global progress and sustainability. Int J Qual Health Care. 2018;30(10):823–31. https://doi.org/10.1093/intqhc/mzy242
Anklam E, Bahl MI, Ball R, et al. Emerging technologies and their impact on regulatory science. Exp Biol Med. 2022;247(1):1–75. https://doi.org/10.1177/15353702211052280
Maeda A, Socha-Dietrich K. Skills for the future health workforce: preparing health professionals for people-centred care. OECD Health Working Papers. Paris: OECD Publishing,; 2021.
Reich MR, Javadi D, Ghaffar A. Introduction to the special issue on effective leadership for health systems. Health Syst Reform. 2016;2(3):171–5. https://doi.org/10.1080/23288604.2016.1223978
Shaw J, Brewer LC, Veinot T. Recommendations for health equity and virtual care arising from the COVID-19 pandemic: narrative review. JMIR Form Res. 2021;5(4):e23233. https://doi.org/10.2196/23233
Graham R, Woodhead T. Leadership for continuous improvement in healthcare during the time of COVID-19. Clin Radiol. 2021;76(1):67–72. https://doi.org/10.1016/j.crad.2020.08.008
Parr JM, Teo S, Koziol-McLain J. A quest for quality care: exploration of a model of leadership relationships, work engagement, and patient outcomes. J Adv Nurs. 2021;77(1):207–20. https://doi.org/10.1111/jan.14583
Ree E, Wiig S. Linking transformational leadership, patient safety culture and work engagement in home care services. Nurs Open. 2020;7(1):256–64. https://doi.org/10.1002/nop2.386
Wu X, Hayter M, Lee AJ, et al. Positive spiritual climate supports transformational leadership as means to reduce nursing burnout and intent to leave. J Nurs Manag. 2020;28(4):804–13. https://doi.org/10.1111/jonm.12994
West M, Armit K, Loewenthal L, et al. Leadership and leadership development in health care: the evidence base. London: The King’s Fund; 2015.
Google Scholar
Churruca K, Ellis LA, Pomare C, et al. Dimensions of safety culture: a systematic review of quantitative, qualitative and mixed methods for assessing safety culture in hospitals. BMJ Open. 2021;11(7):e043982. https://doi.org/10.1136/bmjopen-2020-043982
Smallwood N, Bismark M, Willis K. Burn-out in the health workforce during the COVID-19 pandemic: opportunities for workplace and leadership approaches to improve well-being. BMJ Lead. 2023;leader–2022. https://doi.org/10.1136/leader-2022-000687
Kelly RJ, Hearld LR. Burnout and leadership style in behavioral health care: a literature review. J Behav Health Serv Res. 2020;47(4):581–600. https://doi.org/10.1007/s11414-019-09679-z
Hutchinson K, Ryder T, Coleman H, et al. Determining the role and responsibilities of the community epilepsy nurse in the management of epilepsy. J Clin Nurs. 2023;32(13–14):3730–45. https://doi.org/10.1111/jocn.16582
Mianda S, Voce A. Developing and evaluating clinical leadership interventions for frontline healthcare providers: a review of the literature. BMC Health Serv Res. 2018;18(1):1–15. https://doi.org/10.1186/s12913-018-3561-4
Veronesi G, Kirkpatrick I, Vallascas F. Clinicians on the board: what difference does it make? Soc Sci Med. 2013;77:147–55. https://doi.org/10.1016/j.socscimed.2012.11.019
Ferreira TDM, de Mesquita GR, de Melo GC, et al. The influence of nursing leadership styles on the outcomes of patients, professionals and institutions: an integrative review. J Nurs Manag. 2022;30(4):936–53. https://doi.org/10.1111/jonm.13592
Boamah SA. Emergence of informal clinical leadership as a catalyst for improving patient care quality and job satisfaction. J Adv Nurs. 2019;75(5):1000–9. https://doi.org/10.1111/jan.13895
Dickinson H, Ham C. Engaging doctors in leadership: review of the literature. Birmingham: University of Birmingham; 2008.
Hershkovich O, Gilad D, Zimlichman E, et al. Effective medical leadership in times of emergency: a perspective. Disaster Mil Med. 2016;2:1–5. https://doi.org/10.1186/s40696-016-0013-8
Stoller JK. Developing physician-leaders: a call to action. J Gen Intern Med. 2009;24:876–8. https://doi.org/10.1007/s11606-009-1007-8
Warren OJ, Carnall R. Medical leadership: why it’s important, what is required, and how we develop it. Postgrad Med J. 2011;87(1023):27–32. https://doi.org/10.1136/pgmj.2009.093807
Griffith R. NHS management inquiry: report to the secretary of state for social services. London: Department of Health and Social Security; 1983.
Braithwaite J. Changing how we think about healthcare improvement. BMJ. 2018;361. https://doi.org/10.1136/bmj.k2014
Clay-Williams R, Ludlow K, Testa L, et al. Medical leadership, a systematic narrative review: do hospitals and healthcare organisations perform better when led by doctors? BMJ Open. 2017;7(9):e014474. https://doi.org/10.1136/bmjopen-2016-014474
Nieuwboer MS, van der Sande R, van der Marck MA, et al. Clinical leadership and integrated primary care: a systematic literature review. Eur J Gen Pract. 2019;25(1):7–18. https://doi.org/10.1080/13814788.2018.1515907
Dwyer AJ. Roles, attributes and career paths of medical administrators in public hospitals: survey of victorian metropolitan directors of Medical services. Aust Health Rev. 2010;34(4):506–13. https://doi.org/10.1071/AH09750
Dwyer AJ. Medical managers in contemporary healthcare organisations: a consideration of the literature. Aust Health Rev. 2010;34(4):514–22. https://doi.org/10.1071/AH09736
Health Workforce Australia. Health LEADS Australia: the Australian health leadership framework. Adelaide: Health Workforce Australia; 2013.
NHS Institute for Innovation and Improvement and Academy of Medical Royal Colleges. Medical leadership competency framework: enhancing engagement in medical leadership. Coventry: NHS Institute for Innovation and Improvement; 2010.
National Centre for Healthcare Leadership. NCHL Health Leadership Competency Model 3.0. National Centre for Healthcare Leadership. 2022. https://www.nchl.org/research/ . Accessed 28 December, 2023.
NHS Leadership Academy. Healthcare Leadership Model: the nine dimensions of leadership behaviour. Leeds: NHS Leadership Academy; 2013.
Frank JR, Snell L, Sherbino J, et al. CanMEDS 2015 Physician Competency Framework. Royal College of Physicians and Surgeons of Canada; 2015.
Dath DCM-K, Anderson G, Burke A, Razack S, Lieff S, Moineau G, Chiu A, Ellison P. Leader. In: Frank JRSL, Sherbino J, editors. CanMEDS 2015 Physician Competency Framework. Royal College of Physicians and Surgeons of Canada; 2015.
Royal Australasian College of Medical Administrators. Medical Leadership and Management Curriculum Framework. Malvern, Victoria: Royal Australasian College of Medical Administrators; 2011.
Best S, Stark Z, Brown H, et al. The leadership behaviors needed to implement clinical genomics at scale: a qualitative study. Genet Med. 2020;22(8):1384–90. https://doi.org/10.1038/s41436-020-0818-1
Thoma B, Karwowska A, Samson L, et al. Emerging concepts in the CanMEDS physician competency framework. Can Med Educ J. 2023;14(1):4–12. https://doi.org/10.36834/cmej.75591
Ahern S, Loh E. Leadership during the COVID-19 pandemic: building and sustaining trust in times of uncertainty. BMJ Lead. 2020;leader–2020. https://doi.org/10.1136/leader-2020-000271
Braithwaite J, Churruca K, Hibbert P, et al. At the heart of getting things done in complex healthcare ecosystems: leadership, strategy, sensemaking and sensegiving. In: Chambers N, editor. Research Handbook on Leadership in Healthcare. Edward Elgar Publishing; 2023. pp. 775–92.
Braithwaite J, Fisher G. Beyond the aspirational: creating the future of health care in Australia. Int Med J. 2024;54(2):342–7. https://doi.org/10.1111/imj.16286
Cernega A, Nicolescu DN, Meleșcanu Imre M, et al. Volatility, uncertainty, complexity, and ambiguity (VUCA) in healthcare. Healthc. 2024;12(7):773. https://doi.org/10.3390/healthcare12070773
Kasula BY. Revolutionizing healthcare delivery: innovations and challenges in supply chain management for improved patient care. Trans Latest Trends Health Sect. 2023;15(15).
Niaz M, Nwagwu U. Managing healthcare product demand effectively in the post-covid-19 environment: navigating demand variability and forecasting complexities. Am J Econ Manag Bus. 2023;2(8):316–30. https://doi.org/10.58631/ajemb.v2i8.55
Thirumalai S, Devaraj S. Mitigating the curse of complexity: the role of focus and the implications for costs of care. J Oper Manag. 2024;70(1):157–79. https://doi.org/10.1002/joom.1278
Savage M, Savage C, Brommels M, et al. Medical leadership: boon or barrier to organisational performance? A thematic synthesis of the literature. BMJ Open. 2020;10(7):e035542. https://doi.org/10.1136/bmjopen-2019-035542
Ahti M, Taipale-Walsh L, Kuha S, et al. Health-care leaders’ experiences of the competencies required for crisis management during COVID-19: a systematic review of qualitative studies. Leadersh Health Serv. 2023. https://doi.org/10.1108/LHS-10-2022-0104
Krasikova DV, Green SG, LeBreton JM. Destructive leadership: a theoretical review, integration, and future research agenda. J Manag. 2013;39(5):1308–38. https://doi.org/10.1177/0149206312471388
Pellegrini MM, Ciampi F, Marzi G, et al. The relationship between knowledge management and leadership: mapping the field and providing future research avenues. J Knowl Manag. 2020;24(6):1445–92. https://doi.org/10.1108/JKM-01-2020-0034
Paré G, Trudel M-C, Jaana M, et al. Synthesizing information systems knowledge: a typology of literature reviews. Inf Manag. 2015;52(2):183–99. https://doi.org/10.1016/j.im.2014.08.008
Heath A, Levay P, Tuvey D. Literature searching methods or guidance and their application to public health topics: a narrative review. Health Info Libr J. 2022;39(1):6–21. https://doi.org/10.1111/hir.12414
Adams J, Hillier-Brown FC, Moore HJ, et al. Searching and synthesising ‘grey literature’and ‘grey information’in public health: critical reflections on three case studies. Syst Rev. 2016;5(1):1–11. https://doi.org/10.1186/s13643-016-0337-y
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73. https://doi.org/10.7326/M18-0850
Wolters Kluwer Health I. Get to know the advantages of Ovid MEDLINE ® . 2024. https://tools.ovid.com/ovidtools/medline.html . Accessed.
Stansfield C, Dickson K, Bangpan M. Exploring issues in the conduct of website searching and other online sources for systematic reviews: how can we be systematic? Syst Rev. 2016;5:1–9. https://doi.org/10.1186/s13643-016-0371-9
Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:1–10. https://doi.org/10.1186/s13643-016-0384-4
Peters MD, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119–26. https://doi.org/10.11124/JBIES-20-00167
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32. https://doi.org/10.1080/1364557032000119616
Best S, Long J, Stark Z, et al. Clinical leadership and genomics - what works? Twin Res Hum Genet. 2019;22(5):350. 43rd Annual Scientific Meeting of the Human Genetics Society of Australasia, HGSA 2019. Wellington New Zealand.
Crabtree BF, Howard J, Miller WL, et al. Leading innovative practice: leadership attributes in LEAP practices. Milbank Q. 2020;98(2):399–445. https://doi.org/10.1111/1468-0009.12456
Woiceshyn J, Huq JL, Kannappan S, et al. We need to work differently in a crisis: peer-professional leadership to redesign physicians’ work. BMJ Lead. 2022;6(2):98–103. https://doi.org/10.1136/leader-2021-000490
Appelbaum NP, Liang C, Whitney SE, et al. What business competencies are needed for the modern physician leader and when. Physician Leadersh J. 2022;9(2):39–45.
Hopkins J, Fassiotto M, Ku MC, et al. Designing a physician leadership development program based on effective models of physician education. Health Care Manage Rev. 2018;43(4):293–302. https://doi.org/10.1097/HMR.0000000000000146
Sandberg DS, Pennington CM, Lindquist MA. Virtual leadership: CEOs and C-Level executives of healthcare organizations in the United States reimagined new roles as virtual leaders. J Leadersh Stud. 2022;16(3):61–9. https://doi.org/10.1002/jls.21827
Satiani B, Dawson K, Mehta LS, et al. Lessons learned after implementing an academic faculty leadership program over seven years. Physician Leadersh J. 2022;9(2):30–8.
Angood PB. Transitions and transformations — our choice? Physician Leadersh J. 2022;9(5):6–8.
Brace R, James D. Adapting to changing roles. J Healthc Manag. 2020;35(3):46–7.
Wright C, Pister K. New thinking leads to better transitions. Physician Leadersh J. 2018;5(1):38–40.
Ramirez B, West DJ Jr, Ramirez CL. Healthcare and leadership competencies, training methods, and venues. J Leadersh Acc Ethics. 2021;18(4):93–9.
Wain MJ, Handel DA, Williford K, et al. Transitioning from physician to hospital leader: a competency-based model. Physician Leadersh J. 2020;7(2):32–3.
Borgwardt HL, Botz CT, Doppler JM, et al. Electronic health record implementation: the people side of change. Manage Healthc. 2019;4(1):7–20.
Anandaciva S. The biggest hospital in England. The King’s Fund . 2020. https://www.kingsfund.org.uk/blog/2020/09/biggest-hospital-england . Accessed 25 February, 2023.
Bailey S, West M. Learning from staff experiences of Covid-19: let the light come streaming in. The King’s Fund . 2020. https://www.kingsfund.org.uk/blog/2020/06/learning-staff-experiences-covid-19 . Accessed 26 February, 2023.
Bailey S, West M. Naming the issue: chronic excessive workload in the NHS. The King’s Fund . 2021. https://www.kingsfund.org.uk/blog/2021/06/naming-issue-chronic-excessive-workload-nhs . Accessed 26 February, 2023.
Bhopal A, Hood G. From disaster preparedness to digital disruption: A whistle-stop tour through public health. Faculty of Medical Leadership and Management. 2018. https://www.fmlm.ac.uk/news-opinion/from-disaster-preparedness-to-digital-disruption-a-whistle-stop-tour-through-public . Accessed 27 February, 2023.
Cheetham J. How Leaders in Healthcare 2020 gave an enlightened spotlight to junior doctor leadership. Faculty of Medical Leadership and Management. 2021. https://www.fmlm.ac.uk/news-opinion/how-leaders-in-healthcare-2020-gave-an-enlightened-spotlight-to-junior-doctor . Accessed 27 February, 2023.
Collins B. Leadership and innovation during Covid-19: lessons from the Cardiff and Vale Health System. The King’s Fund . 2021. https://www.kingsfund.org.uk/blog/2021/05/leadership-innovation-covid-19-cardiff-vale . Accessed 27 February, 2023.
Cottey L. The trainee and the team. Faculty of Medical Leadership and Management. 2018. https://www.fmlm.ac.uk/news-opinion/the-trainee-and-the-team . Accessed 28 February, 2023.
Dixon M. Engaging the public in designing the future for the NHS. The King’s Fund . 2018. https://www.kingsfund.org.uk/blog/2018/01/engaging-public-designing-future-nhs . Accessed 28 February, 2023.
Leveson D. Developing clinical leaders through innovation. The King’s Fund . 2021. https://www.kingsfund.org.uk/blog/2021/03/developing-clinical-leaders-through-innovation . Accessed 25 February, 2023.
Naylor C. Getting to grips with climate change: how can the NHS get to net zero? The King’s Fund . 2020. https://www.kingsfund.org.uk/blog/2020/01/climate-change-nhs-net-zero . Accessed 19 February, 2023.
Tweedie J. Leadership - so what is it anyway? February, 2018. https://www.fmlm.ac.uk/news-opinion/blog/leadership-so-what-is-it-anyway
Faculty of Medical Leadership and Management. FMLM response to HEE’s Call for Evidence on the Future Doctor. Faculty of Medical Leadership and Management. 2019. https://www.fmlm.ac.uk/news-opinion/fmlm-response-to-hees-call-for-evidence-on-the-future-doctor . Accessed 23 February, 2023.
Faculty of Medical Leadership and Management. Supporting and developing a leading resource for the future. Faculty of Medical Leadership and Management. 2021. https://www.fmlm.ac.uk/news-opinion/supporting-and-developing-a-leading-resource-for-the-future . Accessed 27 February, 2023.
Faculty of Medical Leadership and Management. Support, wellbeing and leadership. Faculty of Medical Leadership and Management. 2021. https://www.fmlm.ac.uk/news-opinion/support-wellbeing-and-leadership . Accessed 27 February, 2023.
Faculty of Medical Leadership and Management. Reflections from the International Healthcare Leadership Conference. 2022. Faculty of Medical Leadership and Management. 2022. https://www.fmlm.ac.uk/news-opinion/reflections-from-the-international-healthcare-leadership-conference-2022 . Accessed 27 February, 2023.
Lakhani M, Osuji N, Lees P et al. FMLM statement: racism and good leadership are incompatible. Faculty of Medical Leadership and Management. 2020. https://www.fmlm.ac.uk/news-opinion/fmlm-statement-racism-and-good-leadership-are-incompatible . Accessed 28 February, 2023.
Dougall D, Ross S. Transformational change in health and care: reports from the field. 2018. Accessed February, 2023. The King’s Fund.
Fogden R, Buck D, Franklin B et al. Poverty and the health and care system: the role of data and partnership in bringing change. The King’s Fund . 2022. https://www.kingsfund.org.uk/publications/poverty-health-care-system-data-partnership . Accessed 27 February, 2023.
Ham C, Murray R. The NHS 10-year plan: how should the extra funding be spent. The King’s Fund . 2018. https://www.kingsfund.org.uk/publications/nhs-10-year-plan . Accessed 28 February, 2023.
Swanwick T, McKimm J. The assessment of leadership development in the medical undergraduate curriculum: a consensus statement. Faculty of Medical Leadership and Management. 2020. https://www.fmlm.ac.uk/resources/the-assessment-of-leadership-development-in-the-medical-undergraduate-curriculum-a . Accessed 22 February, 2023.
Evans P. A radical upward shift to benefit members and fellows. Faculty of Medical Leadership and Management. 2020. https://www.fmlm.ac.uk/news-opinion/a-radical-upward-shift-to-benefit-members-and-fellows . Accessed 22 February, 2023.
Lakhani M. Black History Month and why it matters. Faculty of Medical Leadership and Management. 2021. https://www.fmlm.ac.uk/news-opinion/black-history-month-and-why-it-matters . Accessed 28 February, 2023.
Moralee S, Exworthy M, Rajasingam D et al. What next for medical leaders? Faculty of Medical Leadership and Management. 2018. https://www.fmlm.ac.uk/resources/what-next-for-medical-leaders . Accessed 25 February, 2023.
Warren S, Laverty A. Leading with compassion: supporting the health and wellbeing of NHS staff. The King’s Fund . 2022. https://www.kingsfund.org.uk/audio-video/podcast/leading-compassion-health-wellbeing-nhs-staff . Accessed 22 February, 2023.
Hancock M. Matt Hancock at The King’s Fund annual conference 2018. 2018. https://www.kingsfund.org.uk/audio-video/matt-hancock-kings-fund-annual-conference-2018 . Accessed.
Olsson-Brown A, Interview with Dr Anna Olsson-Brown - Chair of the Academy of Medical Royal Colleges Trainee Group. Faculty of Medical Leadership and Management. 2020. https://www.fmlm.ac.uk/news-opinion/interview-with-dr-anna-olsson-brown-chair-of-the-academy-of-medical-royal-colleges . Accessed 19 February, 2023.
Denicolai S, Previtali P. Innovation strategy and digital transformation execution in healthcare: the role of the general manager. Technovation. 2023;121:102555. https://doi.org/10.1016/j.technovation.2022.102555
Borges do Nascimento IJ, Abdulazeem H, Vasanthan LT, et al. Barriers and facilitators to utilizing digital health technologies by healthcare professionals. NPJ Digit Med. 2023;6(1):161. https://doi.org/10.1038/s41746-023-00899-4
Braithwaite J, Churruca K, Ellis LA, et al. Complexity science in healthcare: aspirations, approaches, applications, and accomplishments. A white paper. Sydney: Australian Institute of Health Innovation, Macquarie University; 2017.
Coiera E. Why system inertia makes health reform so difficult. BMJ. 2011;342 https://doi.org/10.1136/bmj.d3693
Clay-Williams R, Travaglia J, Hibbert P, et al. Clinical Governance Framework. A Report prepared for the Royal Australasian College of Medical Administrators (RACMA). Melbourne: RACMA; 2017.
Plsek PE, Wilson T. Complexity, leadership, and management in healthcare organisations. BMJ. 2001;323(7315):746–9. https://doi.org/10.1136/bmj.323.7315.746
van Diggele C, Burgess A, Roberts C, et al. Leadership in healthcare education. BMC Med Educ. 2020;20:1–6. https://doi.org/10.1186/s12909-020-02288-x
Golden RE, Klap R, Carney DV, et al. Promoting learning health system feedback loops: experience with a VA practice-based research network card study. Healthc. 2021;8:100484. https://doi.org/10.1016/j.hjdsi.2020.100484
Smith CL, Fisher G, Dharmayani PNA, et al. Progress with the Learning Health System 2.0: a rapid review of Learning Health Systems’ responses to pandemics and climate change. BMC Med. 2024;22(1):131. https://doi.org/10.1186/s12916-024-03345-8
Hunt RC, Struminger BB, Redd JT, et al. Virtual peer-to-peer learning to enhance and accelerate the health system response to COVID-19: the HHS ASPR Project ECHO COVID-19 Clinical rounds Initiative. Ann Emerg Med. 2021;78(2):223–8. https://doi.org/10.1016/j.annemergmed.2021.03.035
Mander R, Hellert U, Antoni CH. Self-leadership strategies for coping with flexibility requirements of digital work with a high degree of latitude for time, place and scope for action—a qualitative study. Gr Interakt Org. 2021;52:163–71. https://doi.org/10.1007/s11612-021-00560-2
Vay C, Steinherr V. Leadership in a digitalized and crisis-ridden world: towards a comprehensive overview of relevant competencies for leaders. University of Hawaiʻi at Mānoa; 2023.
Churruca K, Pomare C, Ellis LA, et al. Patient-reported outcome measures (PROMs): a review of generic and condition‐specific measures and a discussion of trends and issues. Health Expect. 2021;24(4):1015–24. https://doi.org/10.1111/hex.13254
Best A, Greenhalgh T, Lewis S, et al. Large-system transformation in health care: a realist review. Milbank Q. 2012;90(3):421–56. https://doi.org/10.1111/j.1468-0009.2012.00670.x
Bolden R, Kars-Unluoglu S, Jarvis C, et al. Paradoxes of multi-level leadership: insights from an integrated care system. J Change Manag. 2023;23(4):337–57. https://doi.org/10.1080/14697017.2023.2234388
Braithwaite J, Dammery G, Spanos S, et al. Learning health systems 2.0: future-proofing healthcare against pandemics and climate change. A White Paper. Sydney: Australian Institute of Health Innovation, Macquarie University; 2023.
Download references
The authors thank Mary Simons and Jeremy Cullis for their specialist guidance on database searches.
This work was funded in part by RACMA. RACMA contributed to the conceptualization and design of the research. JB is funded and supported by an NHMRC Leadership Investigator Award (1176620).
Authors and affiliations.
Centre for Healthcare Resilience and Implementation Science, Australian Institute of Health Innovation, Macquarie University, 75 Talavera Rd, North Ryde, Sydney, NSW, 2109, Australia
Samantha Spanos, Elle Leask, Romika Patel, Michael Datyner & Jeffrey Braithwaite
Royal Australasian College of Medical Administrators, Melbourne, VIC, Australia
You can also search for this author in PubMed Google Scholar
JB and SS led the research conception and design. SS, ELe, and RP executed the research, and acquired, and analyzed the data. JB, SS, and MD significantly contributed to the interpretation of the data. SS wrote the original manuscript draft which was critically reviewed by JB, ELe, RP, MD and ELo. SS led the manuscript revisions with significant contribution from JB, and input from ELe, RP, MD, and ELo. All authors agree on the journal to which the article will be submitted, have reviewed, and approved the manuscript, and agree to be personally accountable for its contents.
Correspondence to Samantha Spanos .
Ethics approval and consent to participate.
Not applicable.
Competing interests.
The authors declare no competing interests.
Publisher’s note.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
Rights and permissions.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Reprints and permissions
Cite this article.
Spanos, S., Leask, E., Patel, R. et al. Healthcare leaders navigating complexity: a scoping review of key trends in future roles and competencies. BMC Med Educ 24 , 720 (2024). https://doi.org/10.1186/s12909-024-05689-4
Download citation
Received : 13 February 2024
Accepted : 21 June 2024
Published : 03 July 2024
DOI : https://doi.org/10.1186/s12909-024-05689-4
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
ISSN: 1472-6920
This study aims to determine the relationship between judicial protection of intellectual property rights (IPRs), innovation, and firm performance. Using the establishment of intellectual property courts (IPCs) by the Chinese government in Beijing, Shanghai, and Guangzhou in 2014 as a quasi-natural experiment, we build a difference in differences model to assess the impact of legal regulation on firm performance from a judicial perspective. The results show that the IPC reform significantly promotes the growth of firm performance, and this incentive effect is realized through the innovation quality mechanism. For different enterprises, the effect of IPC policy is more evident among firms with strong external funding dependence, large enterprise size, large spillover effects, and state ownership. In addition, we calculated sustainability indicators for firms and found that IPCs increased firms’ total factor productivity through quality-based innovation mechanisms. The important contribution of this study is that it fills a research gap in examining the impact of legal regulation on firms from a judicial perspective by identifying the relationship between judicial protection of IPRs, innovation, and business performance. This paper has implications for the promotion of judicial reform in countries with weak IPR systems, for developing countries like China, the judicial protection of IPRs should be increased to provide an institutional environment more conducive to enterprise development.
This is a preview of subscription content, log in via an institution to check access.
Subscribe and save.
Price excludes VAT (USA) Tax calculation will be finalised during checkout.
Instant access to the full article PDF.
Rent this article via DeepDyve
Institutional subscriptions
The data that support the findings of this study are available from the corresponding author upon reasonable request.
According to the Global Innovation Index Report 2021 released by the World Intellectual Property Organization (WIPO), China ranks 12th in the world in terms of the innovation index and has achieved a steady increase in innovation performance for nine consecutive years beginning in 2013, with the number of patents and trademark applications at the world’s leading level.
Abdallah, A. B., & Al-Ghwayeen, W. S. (2020). Green supply chain management and business performance: The mediating roles of environmental and operational performances. Business Process Management Journal, 26 (2), 489–512. https://doi.org/10.1108/BPMJ-03-2018-0091
Article Google Scholar
Aghion, P., & Howitt, P. (1992). A model of growth through creative destruction. Econometrica, 60 (2), 323–351. https://doi.org/10.2307/2951599
Aghion, P., Reenen, J. V., & Zingales, L. (2013). Innovation and institutional ownership. American Economic Review, 103 (1), 277. https://doi.org/10.1257/aer.103.1.277
Ahmed, E. M. (2017). ICT and human capital spillover effects in achieving sustainable East Asian knowledge-based economies: Erratum. Journal of the Knowldege Economy, 8 (3), 1113. https://doi.org/10.1007/s13132-017-0474-0
Ahmed, E. M. (2020). Modelling green productivity spillover effects on sustainability. World Journal of Science Technology and Sustainable Development, 17 (3), 257–267. https://doi.org/10.1108/WJSTSD-01-2020-0009
Ahmed, E. M. (2021). Modelling information and communications technology cyber security externalities spillover effects on sustainable economic growth. Journal of the Knowldege Economy, 12 (1), 412–430. https://doi.org/10.1007/s13132-020-00627-3
Ahmed, E. M., & Kialashaki, R. (2023). FDI inflows spillover effect implications on the Asian-Pacific labour productivity. International Journal of Finance and Economics, 28 (1), 575–588. https://doi.org/10.1002/ijfe.2437
Akcigit, U., Baslandze, S., & Stantcheva, S. (2016). Taxation and the international mobility of inventors. American Economic Review, 106 (10), 2930–2981. https://doi.org/10.1257/aer.20150237
Allred, B. B., & Park, W. G. (2007). Patent rights and innovative activity: Evidence from national and firm-level data. Journal of International Business Studies, 38 (6), 878–900. https://doi.org/10.1057/palgrave.jibs.8400306
Amore, M. D., Schneider, C., & Žaldokas, A. (2013). Credit supply and corporate innovation. Journal of Financial Economics, 109 (3), 835–855. https://doi.org/10.1016/j.jfineco.2013.04.006
Andries, P., & Faems, D. (2013). Patenting activities and firm performance: Does firm size matter? Journal of Product Innovation Management, 30 (6), 1089–1098. https://doi.org/10.1111/jpim.12047
Ang, J. S., Cheng, Y., & Wu, C. (2014). Does enforcement of intellectual property rights matter in China? Evidence from financing and investment choices in the high-tech industry. Review of Economics and Statistics, 96 (2), 332–348. https://doi.org/10.2139/ssrn.1357045
Anton, J., Greene, H., & Yao, D. A. (2006). Policy implications of weak patent rights. Innovation Policy and the Economy, 6 , 1–26. https://doi.org/10.1086/ipe.6.25056178
Ardito, L., D’Adda, D., & Petruzzelli, A. M. (2018). Mapping innovation dynamics in the Internet of Things domain: Evidence from patent analysis. Technological Forecasting and Social Change, 136 , 317–330. https://doi.org/10.1016/j.techfore.2017.04.022
Barber, B. M., & Lyon, J. D. (1996). Detecting abnormal operating performance: The empirical power and specification of test statistics. Journal of Financial Economics, 41 (3), 359–399. https://doi.org/10.1016/0304-405X(96)84701-5
Baum, L. (2009). Probing the effects of judicial specialization. Duke Law Journal, 58 (7), 1668–1684.
Google Scholar
Bennouri, M., Chtioui, T., Nagati, H., & Nekhili, M. (2018). Female board directorship and firm performance: What really matters? Journal of Banking and Finance, 88 , 267–291. https://doi.org/10.1016/j.jbankfin.2017.12.010
Bhaumik, S. K., & Selarka, E. (2012). Does ownership concentration improve M&A outcomes in emerging markets: Evidence from India. Journal of Corporate Finance, 18 (4), 717–726.
Bouet, D. (2015). A study of intellectual property protection policies and innovation in the Indian pharmaceutical industry and beyond. Technovation, 38 , 31–41. https://doi.org/10.1016/j.technovation.2014.10.007
Boulton, T. J. (2023). Property rights and access to equity capital in China. Global Finance Journal, 55 , 100797. https://doi.org/10.1016/j.gfj.2022.100797
Brem, A., Nylund, P. A., & Hitchen, E. (2017). Open innovation and intellectual property rights: How do SMEs benefit from patents, industrial designs, trademarks and copyrights? Management Decision, 55 (6), 1285–1306. https://doi.org/10.1108/md-04-2016-0223
Chen, L., Ping, L., & Song, F. (2010). Property rights protection and corporate R&D: Evidence from China. Journal of Development Economics, 93 (1), 49–62. https://doi.org/10.1016/j.jdeveco.2009.04.006
Ciftci, M., & Cready, W. M. (2011). Scale effects of R&D as reflected in earnings and returns. Journal of Accounting & Economics, 52 (1), 62–80. https://doi.org/10.1016/j.jacceco.2011.02.003
Claessens, S., & Laeven, L. (2003). Financial development, property rights, and growth. Journal of Finance, 58 (6), 2401–2436. https://doi.org/10.1046/j.1540-6261.2003.00610.x
Cremers, K., Ernicke, M., Gaessler, F., Harhoff, D., Helmers, C., & McDonagh, L. (2017). Patent litigation in Europe. European Journal of Law and Economics, 44 (1), 1–44. https://doi.org/10.1007/s10657-016-9529-0
Cui, W., Hicks, J., & Xing, J. (2022). Cash on the table? Imperfect take-up of tax incentives and firm investment behavior. Journal of Public Economics, 208 , 104632. https://doi.org/10.1016/j.jpubeco.2022.104632
De Chaisemartin, C., & D’Haultfoeuille, X. (2020). Two-way fixed effects estimators with heterogeneous treatment effects. American Economic Review, 110 (9), 2964–2996. https://doi.org/10.1257/aer.20181169
De Chaisemartin, C., & D’Haultfoeuille, X. (2024). Difference-in-differences estimators of intertemporal treatment effects. Review of Economics and Statistics , 1–45. https://doi.org/10.1162/rest_a_01414
Desyllas, P., Salter, A., & Alexy, O. (2022). The breadth of business model reconfiguration and firm performance. Strategic Organization, 20 (2), 231–269. https://doi.org/10.1177/1476127020955138
Elfaki, K. E., & Ahmed, E. M. (2024). Digital technology adoption and globalization innovation implications on Asian Pacific green sustainable economic growth. Journal of Open Innovation: Technology, Market, and Complexity, 10 (1), 100221. https://doi.org/10.1016/j.joitmc.2024.100221
Evangelista, A., Ardito, L., Boccaccio, A., Fiorentino, M., Petruzzelli, A. M., & Uva, A. E. (2020). Unveiling the technological trends of augmented reality: A patent analysis. Computers in Industry, 118 , 1–15. https://doi.org/10.1016/j.compind.2020.103221
Fang, L. H., Lerner, J., & Wu, C. (2017). Intellectual property rights protection, ownership, and innovation: Evidence from China. Review of Financial Studies, 30 (7), 2446–2477. https://doi.org/10.1093/rfs/hhx023
Feng, G. (2005). Innovation, future earnings, and market efficiency. Journal of Accounting, Auditing & Finance, 20 , 385–418. https://doi.org/10.1177/0148558X0502000405
Foo, C. T. (2012). Leadership, strategy and culture. Chinese Management Studies, 6 (4), 536–538. https://doi.org/10.1108/cms.2012.32306daa.001
Fu, T., & Jian, Z. (2021). Corruption pays off: How environmental regulations promote corporate innovation in a developing country. Ecological Economics, 183 (5), 106969. https://doi.org/10.1016/j.ecolecon.2021.106969
Galasso, A., & Hong, L. (2017). Tort reform and innovation. Journal of Law and Economics, 60 (3), 385–412. https://doi.org/10.1086/694337
Ginarte, J. C., & Park, W. G. (1997). Determinants of patent rights: A cross-national study. Research Policy, 26 (3), 283–301. https://doi.org/10.1016/s0048-7333(97)00022-x
Greenhalgh, C., & Rogers, M. (2007). The value of intellectual property rights to firms and society. Oxford Review of Economic Policy, 23 (4), 541–567. https://doi.org/10.1093/oxrep/grm035
Guo, F., Bo, Q. W., Tong, X., & Zhang, X. F. (2020). A paradoxical view of speed and quality on operational outcome: An empirical investigation of innovation in high-tech small and medium-sized enterprises. International Journal of Production Economics, 229 , 107780. https://doi.org/10.1016/j.ijpe.2020.107780
Gyedu, S., Tang, H., Menyah, M. V., & Kissi, G. D. (2024). The relationship between intellectual property rights, innovation, and economic development in the G20 and selected developing countries. Journal of the Knowledge Economy https://doi.org/10.1007/s13132-024-01859-3
Habib, M., Abbas, J., & Noman, R. (2019). Are human capital, intellectual property rights, and research and development expenditures really important for total factor productivity? An empirical analysis. International Journal of Social Economics, 46 (6), 756–774. https://doi.org/10.1108/IJSE-09-2018-0472
Hameed, W. U., Nisar, Q. A., & Wu, H. C. (2021). Relationships between external knowledge, internal innovation, firms’ open innovation performance, service innovation and business performance in the Pakistani hotel industry. International Journal of Hospitality Management, 92 , 102745. https://doi.org/10.1016/j.ijhm.2020.102745
Hanel, P. (2008). The use of intellectual property rights and innovation by manufacturing firms in Canada. Economics of Innovation & New Technology, 17 (4), 285–309. https://doi.org/10.1080/10438590701581481
He, S., Liu, J., & Ying, Q. (2023). Externalities of government-oriented support for innovation: Evidence from the national innovative city pilot policy in China. Economic Modelling, 128 , 106503. https://doi.org/10.1016/j.econmod.2023.106503
Hirshleifer, D., Hsu, P. H., & Li, D. (2018). Innovative originality, profitability, and stock returns. Review of Financial Studies, 31 (7), 2553–2605. https://doi.org/10.1093/rfs/hhx101
Hochberg, Y. V., & Lindsey, L. (2010). Incentives, targeting, and firm performance: An analysis of non-executive stock options. Review of Financial Studies, 23 (11), 4148–4186. https://doi.org/10.1093/rfs/hhq093
Holland, L. C., & Elder, E. M. (2006). Employee stock options in compensation agreements: A financing explanation. Journal of Corporate Finance, 12 (2), 367–379. https://doi.org/10.1016/j.jcorpfin.2005.06.002
Hu, M. (2018). Literature review on imitation innovation strategy. American Journal of Industrial and Business Management, 8 (8), 1777–1788. https://doi.org/10.4236/ajibm.2018.88120
Keller, W. (2004). International technology diffusion. Journal of Economic Literature, 42 (3), 752–782. https://doi.org/10.1257/0022051042177685
Kesan, J. P., & Ball, G. G. (2011). Judicial experience and the efficiency and accuracy of patent adjudication: An Empirical analysis of the case for a specialized patent trial court. Harvard Journal of Law & Technology , 24.
Kim, Y. K., Lee, K., Park, W. G., & Choo, K. (2012). Appropriate intellectual property protection and economic growth in countries at different levels of development. Research Policy, 41 (2), 358–375. https://doi.org/10.1016/j.respol.2011.09.003
Kong, D. M., Yang, Y. W., & Wang, Q. (2023). Innovative efficiency and firm value: Evidence from China. Finance Research Letters, 52 , 103557. https://doi.org/10.1016/j.frl.2022.103557
Liang, R., Wen, X., & Zhu, S. (2023). The impact of emission charges on the quality of corporate innovation: Based on the perspective of breakthrough technological innovation. Journal of Cleaner Production, 404 , 136830. https://doi.org/10.1016/j.jclepro.2023.136830
Lin, K. (2023). The impact of intellectual property protection on business performance of high-tech enterprises: The mediating effect of political-business relations. Finance Research Letters, 54 , 103718. https://doi.org/10.1016/j.frl.2023.103718
Liu, S., Du, J., Zhang, W., Tian, X., & Kou, G. (2021). Innovation quantity or quality? The role of political connections. Emerging Markets Review, 48 , 100819. https://doi.org/10.1016/j.ememar.2021.100819
Lu, Y., & Yu, L. (2015). Trade liberalization and markup dispersion: Evidence from China’s WTO accession. American Economic Journal: Applied Economics, 7 (4), 221–253. https://doi.org/10.1257/app.20140350
Mann, R. J., & Sager, T. W. (2007). Patents, venture capital, and software start-ups. Research Policy, 36 (2), 193–208. https://doi.org/10.1016/j.respol.2006.10.002
Moser, P. (2005). How do patent laws influence innovation? Evidence from nineteenth-century world’s fair. American Economic Review, 95 (4), 1214–1236. https://doi.org/10.1257/0002828054825501
Naghavi, A., & Strozzi, C. (2015). Intellectual property rights, diasporas, and domestic innovation. Journal of International Economics, 96 (1), 150–161. https://doi.org/10.1016/j.jinteco.2015.01.007
Nanda, R., & Rhodes-Kropf, M. (2013). Investment cycles and startup innovation. Journal of Financial Economics, 110 (2), 403–418. https://doi.org/10.1016/j.jfineco.2013.07.001
Neves, P. C., Afonso, O., Silva, D., & Sochirca, E. (2021). The link between intellectual property rights, innovation, and growth: A meta-analysis. Economic Modelling, 97 , 196–209. https://doi.org/10.1016/j.econmod.2021.01.019
Pandit, S., Wasley, C. E., & Zach, T. (2011). The effect of research and development (R&D) inputs and outputs on the relation between the uncertainty of future operating performance and R&D expenditures. Journal of Accounting, Auditing and Finance, 26 (1), 121–144. https://doi.org/10.1177/0148558X11400583
Pandit, S., Wasley, C. E., & Zach, T. (2015). The effect of research and development (R&D) inputs and outputs on the relation between the uncertainty of future operating performance and R&D expenditures. Journal of Accounting, Auditing & Finance, 26 (1), 121–144. https://doi.org/10.1177/0148558X11400583
Parra, A. (2019). Sequential innovation, patent policy, and the dynamics of the replacement effect. The RAND Journal of Economics, 50 (3), 568–590. https://doi.org/10.1111/1756-2171.12287
Porta, R. L., Lopez-De-Silanes, F., Shleifer, A., & Vishny, R. W. (1998). Law and finance. Journal of Political Economy, 106 (6), 1113–1155. https://doi.org/10.1086/250042
Prud’homme, D. (2019). Re-conceptualizing intellectual property regimes in international business research: Foreign-friendliness paradoxes facing MNCs in China. Journal of World Business, 54 (4), 399–419. https://doi.org/10.1016/j.jwb.2019.02.002
Rehman, Z. U., Khan, A., & Rahman, A. (2020). Corporate social responsibility’s influence on firm risk and firm performance: The mediating role of firm reputation. Corporate Social Responsibility & Environmental Management, 27 (6), 2991–3005. https://doi.org/10.1002/csr.2018
Sampat, B., & Williams, H. L. (2019). How do patents affect follow-on innovation? Evidence from the human genome. American Economic Review, 109 (1), 203–236. https://doi.org/10.1257/aer.20151398
Somaya, D., & McDaniel, C. A. (2012). Tribunal specialization and institutional targeting in patent enforcement. Organization Science, 23 (3), 869–887. https://doi.org/10.1287/orsc.1110.0669
Tang, Z. (2019). Judicial enforcement of intellectual property rights in China -from technical improvement to institutional reform. Asia Pacific Law Review, 27 (2), 176–197. https://doi.org/10.1080/10192557.2020.1718351
Tong, T. W., He, W., He, Z. L., & Lu, J. (2014). Patent regime shift and firm innovation: Evidence from the second amendment to China’s patent law. Academy of Management Annual Meeting Proceedings, 2014 (1), 14174–14174. https://doi.org/10.5465/ambpp.2014.14174abstract
Visnjic, I., Wiengarten, F., & Neely, A. (2016). Only the brave: Product innovation, service business model innovation, and their impact on performance. Journal of Product Innovation Management, 33 (1), 36–52. https://doi.org/10.1111/jpim.12254
Wang, C. X., Guo, F., & Zhang, Q. P. (2023). How does disruptive innovation influence firm performance? A moderated mediation model. European Journal of Innovation Management, 26 (3), 798–820. https://doi.org/10.1108/EJIM-07-2021-0369
Wang, H. D., Cho, C. C., & Lin, C. J. (2019). Related party transactions, business relatedness, and firm performance. Journal of Business Research, 101 , 411–425. https://doi.org/10.1016/j.jbusres.2019.01.066
Wang, J. Y., Fan, W. L., & Wang, Z. X. (2024). Tax incentives and earnings management: A study based on accelerated depreciation policy in China. Economic Analysis and Policy, 81 , 281–296. https://doi.org/10.1016/j.eap.2023.11.036
Wang, Z. N., Cai, S. H., Liang, H. G., Wang, N. X., & Xiang, E. W. (2021). Intellectual capital and firm performance: The mediating role of innovation speed and quality. International Journal of Human Resource Management, 32 (6), 1222–1250. https://doi.org/10.1080/09585192.2018.1511611
Weatherall, K., & Webster, E. (2014). Patent enforcement: A review of the literature. Journal of Economic Surveys, 28 (2), 312–343. https://doi.org/10.1111/joes.12009
Wyzycka, N., & Hasmath, R. (2017). The impact of the European union’s policy towards China’s intellectual property regime. International Political Science Review, 38 (5), 549–562. https://doi.org/10.1177/0192512116641320
Yao, L., & Rao, Y. (2009). IPRs protection measure and regional differences in China. International Business Research , 2(3). https://doi.org/10.5539/ibr.v2n3p108
Yao, S., Pan, Y., Sensoy, A., Uddin, G. S., & Cheng, F. (2021). Green credit policy and firm performance: What we learn from China. Energy Economics, 101 , 105415. https://doi.org/10.1016/j.eneco.2021.105415
Yu, L., & Zhao, C. (2023). Promote or inhibit? The effect of the whole chain development of intellectual property on manufacturing firm performance. Frontiers in Psychology, 14 , 1100865. https://doi.org/10.3389/fpsyg.2023.1100865
Zhang, L. G., & Lee, N. (2018). Institutional reforms and governance of intellectual property rights in China - The case of specialized intellectual property courts. Queen Mary Journal of Intellectual Property, 8 (1), 59–67. https://doi.org/10.4337/qmjip.2018.01.06
Zhang, Y. F., Li, L. M., & Xu, K. (2022). Do specialized intellectual property courts show a pro-patent propensity? Evidence from China. International Review of Law and Economics, 70 , 106065. https://doi.org/10.1016/j.irle.2022.106065
Zhang, Y., Ma, X., Pang, J., Xing, H., & Wang, J. (2023a). The impact of digital transformation of manufacturing on corporate performance - The mediating effect of business model innovation and the moderating effect of innovation capability. Research in International Business and Finance, 64 , 101890. https://doi.org/10.1016/j.ribaf.2023.101890
Zhang, Y., Wang, J., Chen, J. K., & Liu, W. Z. (2023b). Does environmental regulation policy help improve business performance of manufacturing enterprises? Evidence from China. Environment, Development and Sustainability, 25 (5), 4335–4364. https://doi.org/10.1007/s10668-022-02245-2
Zheng, P. P., Li, Z., & Zhuang, Z. Y. (2023). The impact of judicial protection of intellectual property on digital innovation: Evidence from China. Finance Research Letters, 58 , 104257. https://doi.org/10.1016/j.frl.2023.104257
Zhou, W. C., & Wang, R. (2020). Intellectual property, institutional dynamics, and firm innovation. Science & Public Policy (SPP), 47 (3), 299–312. https://doi.org/10.1093/scipol/scaa004
Download references
National Social Science Fund of China, Grant/Award Number: 18BJY213.
Authors and affiliations.
School of Economics and Management, Wuhan University, No. 16, Luojiashan Road, Wuchang District, Wuhan City, 430072, China
Wang Hao, Liu Chengkui, Yu Yue & Lin Xiaodan
You can also search for this author in PubMed Google Scholar
Correspondence to Liu Chengkui .
Publisher's note.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
Hao, W., Chengkui, L., Yue, Y. et al. Rule of Law Enhancement, Innovation Incentives, and Business Performance: Evidence from China’s IPCs. J Knowl Econ (2024). https://doi.org/10.1007/s13132-024-02195-2
Download citation
Received : 11 December 2023
Accepted : 07 June 2024
Published : 08 July 2024
DOI : https://doi.org/10.1007/s13132-024-02195-2
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
Find support for a specific problem in the support section of our website.
Please let us know what you think of our products and services.
Visit our dedicated information section to learn more about MDPI.
Evaluating the spatial heterogeneity and driving factors of sustainable development level in chengdu with point of interest data and geographic detector model.
2. literature review, 2.1. spatial and temporal evolution of urban land function, 2.2. functional division of land based on administrative space and its defects, 3. methodology, 3.1. case study, 3.2. methods, 3.2.1. evaluation index system of urban sustainable development, 3.2.2. entropy weight method, 3.2.3. k-means algorithm and urban edge identification, 3.2.4. poi and urban functional area division, 3.2.5. geodetector model and driving forces analysis, 4. results and discussion, 4.1. spatial-temporal patterns of urban sustainable development, 4.1.1. temporal perspective analysis, 4.1.2. spatial perspective analysis, 4.1.3. spatiotemporal perspective analysis, 4.2. urban edge identification and urban expansion trend, 4.2.1. threshold determination for urban night light data based on the k-means algorithm, 4.2.2. identification of urban boundaries based on night light data, 4.2.3. urban expansion trend analysis based on land data, 4.3. poi and identification of urban functional zones, 4.4. driving factor analysis, 5. discussion, 6. conclusions, author contributions, data availability statement, conflicts of interest.
Click here to enlarge figure
Primary Index | Secondary Index | Quantification Method | Unit | Abbreviation |
---|---|---|---|---|
Resources utilization | Air quality index | Composite air quality index | - | AQI |
Proportion of cultivated land | Cultivated land area/land area | % | PCL | |
Water resource | Total water resources per capita | 10 m /10 person | WR | |
Per capita output of grain | Total food production/total population | kg/person | OG | |
Annual output value per unit area | Gross value of agricultural, forestry and fisheries production/land area | yuan/km | AOV | |
Happiness index | Public budget | Public budget expenditure per capita | million yuan/person | PB |
Student | Number of students/million | person/million person | STU | |
Number of beds per 1000 person | Number of beds/thousand persons | number/thousand person | BED | |
Scenic Spots | Number of A-listed attractions per district/area of district | number/hectares unit/hectare | SS | |
Economic potential | GDP per unit area | Gross district product/land area | 10 thousand yuan/km | GDPA |
Urbanization rate | Urbanisation rate of resident population | % | UR | |
Number of industrial enterprises above designated size | Number of industrial enterprises above designated size | unit | NIE | |
Average property price | Average annual housing price | yuan | APP | |
Scientific research strength | Percentage of soft science scores for district colleges and universities | % | SRE | |
Incremental effective invention | 12-month cumulative valid inventions | Number | IE | |
Number of listed companies | Number of listed companies | numer | NLC |
Functional Categorization | Medium Categories | POI |
---|---|---|
Happiness index | Public facilities | Public telephone, newspaper and magazine stand service area, public toilet, and shelter et al. |
Science, Education, and Culture | School, training center, research institution, library and cultural palace et al. | |
Medical and Healthcare | Clinic, general hospital, emergency center, and specialist hospital et al. | |
Tourist Attractions | Park, scenic spot, temple, square, zoo, and botanical garden et al. | |
Economic potential | Companies and Enterprises | Company, factory and agriculture, forestry, animal husbandry, and fishery base et al. |
Shopping and Services | Home furnishing, specialty store, shop, comprehensive market, sporting goods store et al. | |
Financial Institutions | Bank, insurance agency, security company et al. | |
Business and Residential Areas | Residential area, building and industrial park et al. | |
Resources utilization | Blank area of POI | - |
Mixed functional area | All | All |
Resources Utilization | Economic Potential | Happiness Index | |||
---|---|---|---|---|---|
Indicators | q-Statistic | Indicators | q-Statistic | Indicators | q-Statistic |
AQI | 0.17 | GDPA | 0.60 | PB | 0.10 |
PCL * | 0.28 | UR * | 0.24 | STU | 0.008 |
WR * | 0.26 | NIE | 0.12 | BED * | 0.48 |
OG * | 0.24 | APP * | 0.50 | SS * | 0.61 |
AOV * | 0.32 | SRE * | 0.55 | - | - |
- | - | IE | 0.74 | - | - |
- | - | NLC * | 0.66 | - | - |
Mean | 0.253 | 0.489 | 0.317 | ||
Variance | 0.002 | 0.044 | 0.054 | ||
Coefficient of variation | 0.193 | 0.43 | 0.733 |
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Ling, Y.; Zhao, Y.; Ren, Q.; Qiu, Y.; Zhang, Y.; Zhai, K. Evaluating the Spatial Heterogeneity and Driving Factors of Sustainable Development Level in Chengdu with Point of Interest Data and Geographic Detector Model. Land 2024 , 13 , 1018. https://doi.org/10.3390/land13071018
Ling Y, Zhao Y, Ren Q, Qiu Y, Zhang Y, Zhai K. Evaluating the Spatial Heterogeneity and Driving Factors of Sustainable Development Level in Chengdu with Point of Interest Data and Geographic Detector Model. Land . 2024; 13(7):1018. https://doi.org/10.3390/land13071018
Ling, Yantao, Yilang Zhao, Qingzhong Ren, Yue Qiu, Yuerong Zhang, and Keyu Zhai. 2024. "Evaluating the Spatial Heterogeneity and Driving Factors of Sustainable Development Level in Chengdu with Point of Interest Data and Geographic Detector Model" Land 13, no. 7: 1018. https://doi.org/10.3390/land13071018
Further information, mdpi initiatives, follow mdpi.
Subscribe to receive issue release notifications and newsletters from MDPI journals
IMAGES
VIDEO
COMMENTS
1. The Classic Literature Gap. First up is the classic literature gap. This type of research gap emerges when there's a new concept or phenomenon that hasn't been studied much, or at all. For example, when a social media platform is launched, there's an opportunity to explore its impacts on users, how it could be leveraged for marketing, its impact on society, and so on.
Show how your research addresses a gap or contributes to a debate; Evaluate the current state of research and demonstrate your knowledge of the scholarly debates around your topic. Writing literature reviews is a particularly important skill if you want to apply for graduate school or pursue a career in research. We've written a step-by-step ...
A literature gap, or research gap, is an unexplored topic revealed during a literature search that has scope for research or further exploration. To identify literature gaps, you need to do a thorough review of existing literature in both the broad and specific areas of your topic. You could go through both the Introduction and Discussion ...
Here are some examples of research gaps that researchers might identify: Theoretical Gap Example: In the field of psychology, there might be a theoretical gap related to the lack of understanding of the relationship between social media use and mental health. Although there is existing research on the topic, there might be a lack of consensus ...
1 Answer to this question. Specifically in the context of doing and writing the literature review, you can identify a gap in any/all of the following ways: Look up papers that build on previous papers, be it by the same author/s or others. Find out what gaps the later papers have addressed, and if there are still any.
Through systematic processes, these reviews offer suggestions to synthesize literature to identify research gaps and indicate research directions. Lastly, this article serves as a guide for researchers and academics in conducting an extensive literature review.
Gap Analysis for Literature Reviews and Advancing Useful Knowledge 1. Figure 1: Abstract example of a causal map of a theory. There are really three basic kinds of gaps for you to find: relevance ...
Mapping the gap. The purpose of the literature review section of a manuscript is not to report what is known about your topic. The purpose is to identify what remains unknown—what academic writing scholar Janet Giltrow has called the 'knowledge deficit'—thus establishing the need for your research study [].In an earlier Writer's Craft instalment, the Problem-Gap-Hook heuristic was ...
As mentioned previously, there are a number of existing guidelines for literature reviews. Depending on the methodology needed to achieve the purpose of the review, all types can be helpful and appropriate to reach a specific goal (for examples, please see Table 1).These approaches can be qualitative, quantitative, or have a mixed design depending on the phase of the review.
Literature Review is a comprehensive survey of the works published in a particular field of study or line of research, usually over a specific period of time, in the form of an in-depth, critical bibliographic essay or annotated list in which attention is drawn to the most significant works. Also, we can define a literature review as the ...
An essential aspect of reviewing the literature is to identify research gaps (Webster and Watson 2002). While reviews oug ht to be conducted rigorously (e.g., Fink 2010), there has been a lack of ...
The identification of gaps from systematic reviews is essential to the practice of "evidence-based research." Health care research should begin and end with a systematic review.1-3 A comprehensive and explicit consideration of the existing evidence is necessary for the identification and development of an unanswered and answerable question, for the design of a study most likely to answer ...
What is a 'gap in the literature'? The gap, also considered the missing piece or pieces in the research literature, is the area that has not yet been explored or is under-explored. This could be a population or sample (size, type, location, etc.), research method, data collection and/or analysis, or other research variables or conditions.
As a final note, remember that many gaps may be filled with secondary research; a new literature review that fills the gaps in the logic/structure, data/information, and meaning/relevance of your map so that your organisation can have a greater impact. Figure 3. Visualizing the gaps (shown in green)
A literature review is a critical analysis and synthesis of existing research on a particular topic. It provides an overview of the current state of knowledge, identifies gaps, and highlights key findings in the literature. 1 The purpose of a literature review is to situate your own research within the context of existing scholarship ...
A literature review is important because it: Explains the background of research on a topic. Demonstrates why a topic is significant to a subject area. Discovers relationships between research studies/ideas. Identifies major themes, concepts, and researchers on a topic. Identifies critical gaps and points of disagreement.
Most literature reviews in information systems (IS) research use the framework proposed by Webster and Watson's (2002). However, their framework includes little information about how to rigorously identify research gaps when conducting literature reviews. As Webster and Watson note, "a review should identify critical knowledge gaps and thus ...
The literature review for a gap in practice will show the context of the problem and the current state of the research. Research gap definition. A research gap exists when: ... To identify research trends, use the literature review matrix to track where further research is needed. Download or create your own Literature Review Matrix (examples ...
How to Write a Literature Review in 6 Steps. Published on July 2, 2024 by Paige Pfeifer, BA. The usual purpose of a literature review is to show a gap in existing research or to show a field's overall view of a topic. A "literature review" is a summary of what previous studies have demonstrated or argued about a topic.
This research question was derived based on the analysis of the existing literature and the gaps identified. Published research provides limited evidence on how the tasks and tools of management accountants are (expected to be) impacted by digitization. Recent studies focus on limited aspects.
Identifying Gaps. If you do not find articles in your literature search, this may indicate a gap. If you do find articles, the goal is to find a gap for contributing new research. Authors signal that there is a gap using phrases such as: Has not been clarified, studied, reported, or elucidated. Further research is required or needed.
1. Evidence Gap: An evidence gap occurs with a provocative exception arising if a new research finding contradicts widely accepted conclusions. This gap involves contradictions in the findings of the prior research. It occurs if results from studies allow for conclusions in their own right, but are contradictory when examined from a more abstract point of view.
The purpose of this paper is to conduct a systematic literature review on the concept of research gaps and provoke a discussion on the contemporary literature on types of research gaps. The paper discusses the various approaches for researchers to identify, align and position research problems, research design, and methodology in the research ...
Section 7 shows research gaps and possible directions for closing them. ... These factors help ensure the 3D packing literature review is efficient, reliable, and suitable. This methodology ensures the literature review is up-to-date and allows obtaining the main body of robotic 3D packing. After applying this methodology, 46 studies were left.
To address this knowledge gap we first conducted a literature review focusing on two research questions: 1) the difference in adherence between SITT and MITT users in COPD, and 2) the effect of smart inhalers on adherence in COPD. Separate searches were conducted in PubMed and two authors independently assessed the articles.
To address this gap, our systematic literature review examined existing literature to further explore and understand visual pollution. We systematically reviewed research articles published between 2008 and 2023, utilizing three journal databases: Web of Science, Scopus, and Google Scholar.
Targeted gray literature search. References were screened according to the inclusion and exclusion criteria (Table 1), except that articles only needed to report (rather than focus) on future leadership roles and requirements.This is because we wanted to ensure that our analysis broadly captured the most recent sources of information on healthcare leadership requirements, even if these sources ...
Literature. A country's IPR regime profoundly affects the ability of firms to function as agents of social innovation. A weak IPR environment reduces firms' access to external finance and forces them to suboptimally allocate resources, thus hindering firm growth (Claessens & Laeven, 2003).Further, although a firm's competitive advantage in the marketplace relies heavily on technological ...
Over the past few decades, China has undergone the largest and fastest urbanization process in world history. By 2023, Chengdu's urbanization rate had reached 80.5%, significantly higher than the national average of 66.16%. Studying the urbanization experience of Chengdu is of great significance for optimizing urban planning policies in Chengdu and other cities in China. Although much ...